Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2007

Comparative Microarray Data Mining
Shihong Mao
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Computer Engineering Commons, and the Computer Sciences Commons

Repository Citation
Mao, Shihong, "Comparative Microarray Data Mining" (2007). Browse all Theses and Dissertations. 217.
https://corescholar.libraries.wright.edu/etd_all/217

This Dissertation is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It
has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

Comparative Microarray Data Mining

A dissertation submitted in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy

By

SHIHONG MAO
M.S., Wright State University, 2001

2007
Wright State University

© Copyright by
Shihong Mao
2007

All Rights Reserved

ii

Wright State University
SCHOOL OF GRADUATE STUDIES
Nov 30th, 2007
I HEREBY RECOMMEND THAT THE DISSERTATION PREPARED UNDER MY
SUPERVISION BY Shihong Mao ENTITLED Comparative Microarray Data Mining BE
ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE
DEGREE OF Doctor of Philosophy.

Guozhu Dong, Ph.D.
Dissertation Director

Thomas A. Sudkamp, Ph.D.
Director, Ph.D. Program of CS&E

Joseph F. Thomas, Jr., Ph.D.
Dean, School of Graduate Studies

Committee on Final Examination:

Guozhu Dong, Ph.D.

Michael L. Raymer, Ph.D.

Mateen M. Rizki, Ph.D.

F. Javier Alvarez-Leefmans, Ph.D., M.D.

Dale E. Courte, Ph.D.

iii

ABSTRACT
Mao, Shihong. Ph.D., Department of Computer Science and Engineering, Wright State
University, 2007. Comparative Microarray Data Mining.

As a revolutionary technology, microarrays have great potential to provide genome-wide
patterns of gene expression, to make accurate medical diagnosis, and to explore genetic
causes underlying diseases. It is commonly believed that suitable analysis of microarray
datasets can lead to achieve the above goals. While much has been done in microarray
data mining, few previous studies, if any, focused on multiple datasets at the comparative
level. This dissertation aims to fill this gap by developing tools and methods for set-based
comparative microarray data mining. Specifically, we mine highly differentiative gene
groups (HDGGs) from given datasets/classes, evaluate the concordance of datasets
generated from different platforms/laboratories, investigate the impact of variability in
microarray dataset on data mining results, provide tools and algorithms for the above
tasks, and identify reliable invariant HDGG patterns for better understanding diseases.
It is a big challenge to discover high-quality discriminating (emerging) patterns from high
dimensional microarray datasets. We develop a novel feature-group selection method to
help discover HDGGs, especially signature HDGGs that completely characterize some
disease classes. In addition to giving insights on the diseases, better classification results
are also obtained using HDGG-based classifiers compared with other existing classifiers.
As microarray datasets are often generated from different platforms/laboratories, it is
necessary to evaluate their concordance/consistence before they can be studied together.
We provide measures and techniques to quantitatively test such concordance at the
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comparative level.
In addition to applying measures to evaluate the degree of variability in microarray
datasets, we also develop a novel algorithm called C-loocv to effectively minimize the
variability. As an indicator of the utility of C-loocv, classifiers trained from C-loocvrefined datasets become more robust and predict test samples at significantly higher
accuracy over classifiers trained from original datasets.
Based on the variability minimization algorithm, we provide a novel strategy to mine
invariant patterns from multiple datasets concerning a common disease. As a
demonstration, invariant patterns are identified from two datasets concerning lung cancer;
these patterns may shed light on the mechanism underlying the pathogenesis of lung
cancer. Our methods are generic and can be applied to microarrays concerning any
human diseases.
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Chapter 1: INTRODUCTION

1.1. MOTIVATION – THE PROSPECT OF MICROARRAY GENE
EXPRESSION DATA
Microarray technology allows the measuring of the expression level of thousands of
genes simultaneously by using gene chips. This technology provides the possibility of
creating datasets that capture the information concerning all the relevant genes and
proteins for many systems of biological and clinical interest. Such datasets may help
scientists explore gene expression patterns and discover gene interaction networks, and
perhaps even pathways underlying various diseases and biological processes. Such
discoveries can in turn lead to better understanding of the physiological functions in
healthy and diseased cells, and to better ways to diagnose and treat diseases. Large-scale
transcription analyses using microarrays can reveal the molecular mechanisms of
physiology and pathogenesis, and therefore can help scientists to develop new diagnostic
and therapeutic strategies.
Recently, microarray (DNA chip) technology is becoming a very important and powerful
tool in almost every field of biomedical research. This technology has been used in
reproductive medical research including study of oocyte fertilization, early embryo
development, implantation and some infertility-related diseases such as endometriosis
and myoma (Chen et al, 2006). Microarray also brings new insights into evolutionary
1

biology by providing genome-wide patterns of gene expression within and between
species (Ranz et al, 2006).
For cancer study, a number of cancer-related datasets such as colon cancer (Alon 1999),
acute lymphoblastic leukemia (Golub 1999), breast cancer (van’t Veer et al 2002) and so
on have been successfully generated using microarray technology in the past decade.
These datasets have also been widely studied by researchers in various fields, and the
analysis results have provided valuable information for biomedical, pharmaceutical, and
clinical research. In the present dissertation several public cancer-related microarray
datasets were employed for data mining. The long-term goal of this project is to provide
useful tools and information aiming at enhancing our understanding of diseases by
developing comparative data mining methods.
Specifically, we develop several novel comparative data mining approaches on
microarray gene expression data, aiming at extracting reliable patterns from microarray
datasets. We propose that comparative data mining of microarray data has the potential to
discover key groups of genes in cancer, which will help us to better understand its pathophysiology. Moreover, this approach will help uncovering new therapeutic targets for
diseases, predicting how patients respond to specific treatments, and revealing possible
regulatory relationships among genes in normal and disease situations.

1.2. OVERVIEW OF RESULTS
In this dissertation, we provide measures, tools and methodologies for the above
mentioned data mining approaches. Below is a summary of the research projects we have
been working on:

2

1. Identification of highly differentiative gene groups (HDGGs) from microarray data.
The aim is to introduce methods that could do a better job given the high dimensionality
challenge. We combine a new approach (gene club formation) with previous data mining
algorithms for feature selection and discovering emerging (discriminating) patterns. The
HDGGs mined from each dataset are considered as discriminative characteristic patterns
and are important features for each specific dataset.
2. Multi-source microarray platform concordance detection. The aim is to provide
measures and techniques to compare microarray gene expression data generated from
different platforms and laboratories. Microarray datasets are generated from different
platforms / laboratories. It is necessary to evaluate the concordance and consistence of the
multi-source microarray datasets before they can be applied to clinical, pharmaceutical
research and other purposes. Since no comparative methods have been applied to test the
concordance of multi-source microarray datasets, we generated several comparative
methods to test such data and measure their concordance with each other.
3. Minimization of microarray dataset variability. The aim is to evaluate the effect of
variability on data mining results and to provide novel methods to minimize it. The
inevitable variability in microarray datasets leads to less reliability and accuracy of mined
patterns and models. We develop a novel method to minimize variability by eliminating
highly noisy samples from datasets.
4. Identification of invariant patterns. The aim is to mine reliable patterns thought to play
key roles in the pathogenesis of diseases. We provide a novel method to mine invariant
patterns from multiple datasets related to a disease in particular. The invariant patterns
(shared gene interactions) are considered as more reliable patterns and expected to
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provide useful information for potential gene pathways for the diseases under
consideration.

1.3. ORGANIZATION OF THE DISSERTATION
This dissertation deals with comparative microarray data mining, and is divided in eight
chapters. Chapter 1 is an introduction chapter. Chapter 2 gives an overview of
preliminary information on gene expression data, and a discussion of some important
concepts which will be applied in other chapters, such as high dimension, high variability
microarray data, emerging patterns, entropy-based discretization method and information
gain. Chapter 3 provides a review of the literature on topics related to the present research.
This chapter discusses what have been done by previous researches, the gaps that exist
between current research and our research goals, and what we want to do in order to fill
these gaps.

Discovery of invariant
patterns
(Chapter 7)
if yes
Reliable?
if yes
Comparable?

Variability evaluation
and minimization
(Chapter 6)

Discovery of HDGGs
(Chapter 4)

Dataset concordance
detection
(Chapter 5)

Multi-source microarray datasets
Figure 1.1: Outline of topics studied in this dissertation.
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Chapters 4 to 7 comprise the results from the scientific research accomplished during the
past 5 years. Chapter 4 introduces the discovery and application of HDGGs. Chapter 5
deals with the detection of concordance of microarray datasets generated from different
platforms / laboratories. Chapter 6 presents our investigation on and the minimization of
biological variation in microarray datasets. Chapter 7 discusses the discovery of invariant
patterns from multi-microarray datasets. Chapter 8 is a summary of our work and future
directions.
The relationship between the topics considered in this dissertation is illustrated in Figure
1.1.

5

Chapter 2: PRELIMINARIES
This chapter deals with background information regarding the techniques and
terminology that will be used throughout this dissertation.

2.1. MICROARRAY GENE EXPRESSION DATA
With the development of microarray technology many kinds of microarray data have
been generated such as: DNA microarrays, protein microarrays, tissue microarrays, cell
microarrays, chemical compound microarrays and antibody microarrays. The most
commonly used ones are DNA microarrays. In this dissertation, “microarrays” refers to
“DNA microarrays”.
A DNA microarray (also commonly known as a gene or genome chip, DNA chip, or gene
array) is a collection of microscopic DNA spots, each representing a gene probe, arrayed
on a solid surface by covalent attachment to chemically suitable matrices. DNA arrays
differ from other types of microarrays only in that they either measure DNA or use DNA
as part of its detection system. Qualitative or quantitative measurements with DNA
microarrays utilize the selective nature of DNA-DNA or DNA-RNA hybridization under
high-stringency conditions and use fluorophore-based detection. DNA microarrays are
commonly used for expression profiling, i.e., monitoring gene expression levels of
thousands of genes simultaneously to determine whether those genes are active,
hyperactive or silent in given tissues.

6

Figure 2.1 shows the step by step procedure to convert each gene’s expression level into a
real numeric value data when using microarrays. 1) A microarray chip is labeled with
gene probes (left column). 2) Total mRNA is extracted from a given sample and labeled
with the corresponding fluorophore, e.g. cy3 or cy5 (middle column). 3) The microarray
is hybridized with labeled mRNA (middle). 4) The microarray is scanned, filtered and
raw data is generated (right column). 5) After data preprocessing and normalization, the
data generated can be used for further analysis and mining. Table 2.1 is an example of
microarray gene expression data with three genes and six tissues (three from normal
control, and three from diseased patients).

Figure 2.1: Microarray technology pipeline
ORF: open reading frame, PCR: polymerase chain reaction
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Table 2.1: A sample microarray gene expression dataset
g1
g2
g3

d1
32.0
5.9
94.4

d2
52.3
1.7
132.7

d3
89.3
2.6
180

N1
51.1
10.0
73.4

n2
29.7
3.2
55.8

n3
4.5
9.1
120.6

d1, d2, d 3: diseased tissues; n 1, n2, n3: normal tissues; g1, g2, g3: genes.
Currently microarray data are generated using various different platforms such as
commercial platforms (Affymetrix, Agilent, Applied Biosystems, etc) or custom-made
ones. The platforms mainly differ on what and how the gene probes are labeled on the
microarray chips. For example, the probes on the Agilent platform are cDNA, which is
reverse-transcribed from known mRNA. The probes can perfectly hybridize with their
corresponding mRNA, although the quality of the probes may greatly affect the
hybridizing results. Affymetrix is probably the most popular commercial platform so far.
The probes are designed based on gene sequence analysis. Each probe on the chip is
designed as one pair of oligonucleotide about 35 mer in length. One oligonucleotide is
the Perfect-Match (PM), and the other one is a one-base pair Mis-Match (MM), with the
corresponding gene. This probe design can effectively reduce noise in microarray data.

2.2. CHARACTERISTICS OF MICROARRAY DATA
Compared with commercial datasets, microarray gene expression datasets have quite
different characteristics. First, their dimensionality, i.e. the number of features explored
in gene chip, is high. The raw microarray images are transformed into gene expression
matrices where the rows usually denote genes or features and the columns denote various
8

samples, conditions, tissues or instances. The number of features (dimensions) can be
very high. Usually, there are usually thousands of gene probes in one gene chip. If a gene
chip is designed to detect all genes in a human tissue sample, the number of probes may
exceed 100,000.
Second, the number of samples may be small, compared with typical commercial
applications. For many biomedical and pathology studies, the number is usually less than
200.
Third, microarray datasets may be very noisy containing unreliable or contaminated
values. In sum, there is high variability in microarray datasets. The variability includes
that inherent to measurement procedures (measurement variability) and biological
variation. Measurement variability results from differences in experimental conditions,
procedures and differences in microarray technologies. Biological variation is due to
intrinsic characteristics of the samples.
Table 2.2: An ideal microarray gene expression dataset
Class A
s1 … sx
g1 a1 … a1
g2 a2 … a2
… … … …
g n an … an

Class B
s1 … sy
b1 … b1
b2 … b2
… … …
bn … bn

Ideally, if there is no variability, each gene’s expression value across the samples within
one class should be identical. Table 2.2 shows a sample microarray gene expression
dataset without variability. There are two classes A and B in this dataset. There are x
samples (s1 to sx) in A and y samples (s1 to sy) in B. Total n gene probes (g1 to gn) are
used to construct the microarray chip. ai and bi are gene gi’s standard values in class A
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and B respectively. Under the ideal situation, gi’s real value in any samples in one class
should be equal to its standard value. In this case, data mining results from this dataset
will be 100% accurate and reliable. Unfortunately this kind of microarray dataset never
exists in reality.
Table 2.3 shows microarray dataset with measurement variability. Each gene’s detected
value aij and bik (1 ≤i ≤ n, 1 ≤j ≤x, 1 ≤k ≤y) is shifted from its standard value by a random
value αij or βik. If αij or β ik is large, then the data have high variability.

Table 2.3: Microarray gene expression dataset with only measurement variability

g1
g2
…
gn

s1
a1± α11
a2± α21
…
an± αn1

Class A
…
sx
…
a1± α1x
…
a2± α2x
…
…
…
an± αnx

s1
b1± β11
b2± β21
…
bn± βn1

Class B
…
sy
…
b 1± β 1y
…
b 2± β 2y
…
…
…
b n± β ny

As mentioned before, besides measurement variability, there is also intrinsic biological
variation in microarray datasets. Microarray datasets are typically generated using tissue
samples from different patients. These patients have different characteristics such as
height, weight, age, race, and sex. These differences inevitably lead to biological
variations in microarray datasets. Because of biological variation, gene gi’s standard
values (ai or bi) can not be measured. In reality, in different samples, the “real” values of
gi are different. For example, in class A, gi’s real value at sample j is aij and gi’s detected
value at sample j will be aij ± αij. Theoretically, gi’s real value should be close to its
standard value within one class; however, in real microarray dataset, some samples have
10

big biological variation because the genes’ real values in these samples are far away from
their standard value.

Table 2.4: Actual microarray gene expression dataset

g1
g2
…
gn

s1
a11± α11
a21± α21
…
an1± αn1

Class A
…
sx
…
a1x± α1x
…
a2x± α2x
…
…
…
anx± αnx

s1
b11± β11
b21± β21
…
bn1± βn1

Class B
…
sy
…
b1y± β 1y
…
b2y± β 2y
…
…
…
bny± β ny

Table 2.4 shows a realistic microarray dataset. Both measurement variability and
biological variation are included. The high variability may affect the reliability of
microarray datasets. During microarray data analysis and data mining, the high variability
should be considered.

2.3. EMERGING PATTERNS AND BORDER DIFFERENTIAL
ALGORITHM
Emerging patterns (EPs) (Dong et al., 1999; Dong et al., 2005) are defined as patterns
whose supports increase significantly from one class to another. EPs with growth rate
(defined as the ratio of frequency between the classes) of infinity are called jumping EP
(JEP), i.e. these patterns appear in one class but never exist in other classes. EPs have
been proved to be very useful as a means of discovering distinctions inherently present
between different classes of data. For example, by using emerging patterns, Li and
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colleagues (Li et al., 2002, Li et al., 2003a, Li et al., 2003b) identified good diagnostic
genes or gene groups from gene expression data of the Acute Lymphoblastic Leukemia
vs Acute Myeloid Leukemia (ALL/AML) dataset (Golub et al., 1999) and other datasets
such as colon cancer (Alon et al., 1999) and ALL (Yeoh et al., 2002).
To efficiently discover the jumping emerging patterns (JEPs) with respect to a positive
dataset and a negative dataset, border manipulation algorithm was proposed (Dong et al.,
1999). The border differential algorithm is the core subroutine for JEP mining and it aims
to derive the difference between a pair of border of a special form. The border based
algorithm achieves high efficiency by manipulating only the itemsets in the borders and
avoiding the tedious process of enumerating all the individual JEPs.

2.4. ENTROPY-BASED DISCRETIZATION METHOD AND
INFORMATION GAIN
Microarray gene expression data are always continuous and contain a large number of
genes. Such data should be pre-processed, through operations including binning,
duplicate gene removal, and gene ranking. Binning transforms continuous features into
discrete features. The entropy based method (Dougherty et al., 1995) is often applied to
convert the values for each gene into two intervals (bins) and to rank the genes. (More
bins can be allowed, but in this dissertation we only consider two bins.) One bin will be
called “high” and the other “low”. Let S be the set of all tuples and T(S, Cj) be the
proportion of tuples in S that have class Cj. The entropy for S is:

Entropy( S ) = −

∑ T (S , C ) * log(T (S , C ))
2

j

j =1
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Let g be a gene. Each value v can divide g’s values into two intervals, namely g ≤ v and g
> v; let S1 (resp., S2) be the set of tuples in S where g’s values are ≤ v (resp., > v). We
define Entropy(Si) similarly as above. The class information for gene g at partition point
v is

I ( g , v) =

| S1 |
|S |
* Entropy( S1 ) + 2 * Entropy( S 2 )
|S|
|S|

where |S| denotes the cardinality of S. The information gain for g at partition point v is:

InfoGain( g , v) = Entropy ( S ) − I ( g , v)
The value v for which InfoGain(g,v) is maximal amongst all the candidate split points is
selected as the split point for g. Let InfoGain(g) denote that maximal InfoGain(g, v).
Information gain for a gene captures how strong the gene is related to the class; the larger
the information gain, the stronger the relationship. We will usually rank the genes in
decreasing information gain order.
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Chapter 3: LITERATURE REVIEW
The main goal of the present dissertation is to find new ways to analyze microarray gene
expression datasets so that we can mine more information out of them and hopefully
provide valuable clues for biological and medical research. One of the strength of this
research is to compare multiple datasets. In addition, microarray analysis and data mining
have potential value as a diagnostic and predictive tool in various researches.
This chapter comprises a survey of the work related to our study, identify the gaps
between previous studies and our research goals, and briefly introduce what we are going
to do to fill those gaps. The main topics include comparative studies and data mining,
feature selection, microarray data concordance detection, biological variation, instance
selection and classification.

3.1. COMPARATIVE STUDIES AND DATA MINING
Comparative studies, aimed at comparing the similarity/difference between groups using
comparative methods, have been applied to many fields, such as genomics, gene function
comparison, text files and microarray datasets. In the field of genomics, comparative
study, commonly named comparative genomics, is used to study the similarities and
differences in the structure and function of hereditary information across species. This
approach is used to compare genomes in genomics comparative data analysis. Recently,
the availability of sequences from numerous biological species has allowed multiple
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species-comparisons for identifying the relationships between species (Hood et al 1995,
Dubchak et al 2000, Pennacchio et al 2001, Gottgens et al 2002). The utility of
comparative sequence analysis is based on the hypothesis that important biological
sequences are conserved between species due to functional constraints.
A number of recent comparative genomics studies, such as the evolutionary distance
comparison between human-mice, human-birds, human-fish and human-primate, have
yielded the identification of functional sequences solely through the use of genomic
comparison. Enormous advances, such as the inference of function of new sequences
through similarity to known sequences, have been made (Boffelli et al, 2003, Kappen et
al, 2003, Harris et al, 2003, Nobrega et al, 2003, Postlethwait et al, 2000, OBrien et al,
1999).
Similarly, comparative studies have been applied on gene function comparison. Lin and
colleagues (Lin et al., 2002) proposed a new concept called “functional genomic units”,
which is a group of genes carrying out some common biological functions. They
described an interesting attempt to use the Rosetta dataset (cDNA platform) to
corroborate a Rac1 transfection obtained from Affymetrix platform.
When data mining approaches are applied to compare different datasets / classes and to
find similarity patterns and unique patterns between these datasets, then the comparative
study is called comparative data mining. Comparative data mining has been applied on
text files, which is named as comparative text mining. Zhai and colleagues (Zhai et al,
2004) proposed a generative probabilistic mixture model for comparative text mining. By
using this model, they discovered certain latent common themes across all collections and
summarized the similarities and differences of these collections along each common
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theme. This approach could be adopted to study microarrays to find common /unique
patterns from mutli-datasets.
If comparative data mining is applied to study microarray datasets, we call it
“comparative microarray gene expression data mining”. This term is first mentioned in
this dissertation and will be its main focus. Comparative data mining is defined as the
mining of similarities and differences/contrasts among multiple data classes or multiple
datasets (each with or without classes).
According to this definition, few papers, if any, can be considered to fall within the
categories of comparative microarray data mining. One paper mentioned comparative
data mining on microarrays (Page et al 2002). The authors used comparative data mining
experiments to compare various classification methods and to identify the advantages of
the leading supervised learning algorithms for microarray data. It should be pointed out
that comparing multiple methods on one dataset will not be considered as comparative
data mining, in the sense defined above.
Many data mining methods focus on feature selection and classification methods by using
microarray data (Li et al 2004). Strictly speaking, building classifiers can not be
considered as comparative data mining, although it is considering two or more classes
and hence it can be loosely considered as comparative mining. Other studies use
comparative methods to analyze microarray data (Xing et al 2001). In their studies, they
use statistical methods other than data mining for microarray data study.
So far, many methods have been proposed for the analysis of microarray data. In general,
some of these methods were borrowed from data mining in other areas and ignored the
intrinsic biological features of microarray data. Most importantly, few of these methods
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considered the high variability in microarray datasets or the concordance between
multiple datasets, which may greatly affect the reliability of data mining results. The
present dissertation addresses these fundamental issues by using comparative microarray
data mining.

3.2. FEATURE SELECTION
Feature selection aims at selecting a subset of relevant features for building robust
learning models. It has been extensively studied in machine learning. Feature selection
helps to improve the performance of learning models by enhancing generalization
capability; speeding up learning processes; and improving model interpretability. In
microarray studies, feature selection is called discriminative gene selection. It selects the
influential genes based on their ability to distinguish between various classes of samples,
such as between different types of diseases or between diseased and healthy states. Thus,
feature selection can help to better understand microarray data, and tell which genes are
important and how they are related with each other.
One characteristic of microarray data is their considerable number of features (genes).
Among these features, not all of them carry relevant information for a particular
application. It is necessary to use feature selection to select the most important
components. From a biological perspective, the most common situation is a group of
genes work together rather than a single gene in the genesis of a disease (Cunliffe et al.,
2003, Califano et al., 2000, Segal et al., 2003). Thus, feature selection is a useful tool to
detect groups of genes from microarray datasets, by considering genes’ interaction with
other genes.
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In gene expression analysis studies, many gene (feature) selection methods have been
developed. These methods include information gain, towing rule, sum minority, max
minority, Gini index, sum of variances, one-dimensional SVM, t–statistics, the ratio of
between-groups to within-groups sum of squares (BSS/ WSS), principal component
analysis among others (Su et al., 2003). Information gain and Gini index are widely used
in machine learning. Towing rule, max minority, sum minority and sum of variances are
broadly applied in statistical learning theory. In these methods, the full range of
expression of a given gene is split into two regions: high or low. Then the strength of this
given gene with respect to the class is evaluated. One-dimensional SVM (Brown et al.,
2000; Ramaswamy et al., 2001) measures the effectiveness of a future by calculating the
accuracy of single-feature SVM classifiers. t -statistics was first used by Golub and
colleagues to measure the class predictability of genes for two-class problems (Golub et
al., 1999).
In many of the methods mentioned above, genes are typically grouped by similarity of
their expression profiles. We suggest a different approach in which genes are grouped
together when correlation of their expression profiles in one state is destroyed in another
state. The correlation considered here is general (e.g., one gene is high whenever another
is low). A highly differentiative gene group (HDGG) is a gene group in which genes are
correlated with each other. A HDGG captures the following information: in the normal
state, some genes are correlated (perhaps because they participate in some common
pathway under normal situation) and are fully “in sync”, but in a disease state these genes
are no longer “in sync” (perhaps because the pathway is disrupted).
Since microarray data have thousands of dimensions, discovery of gene groups, such as
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HDGGs, is a big challenge. Exhaustive search is impossible, since the required search
time grows exponentially with the number of dimensions. Li and colleagues (Li et al.,
2001) use the top-k approach to get around the dimensionality hurdle by selecting the
globally top-k genes in decreasing information gain (Dougherty et al.,1995) order and
then applying the border differential algorithm (Dong et al., 1999, Dong et al., 2005) on
these genes. The border differential algorithm can effectively handle up to 75 genes for
current generation PCs, but can not finish in reasonable amount of time when higher
dimensions are present. As will be shown in Chapter 4, the best HDGGs may contain
genes which are very low in information gain rank, and may be missed by the top-k
method. We aim to introduce methods that are more effective given the dimensionality
challenge.
In order to overcome the high dimension and find HDGGs, we establish gene clubs for
each given gene by using several methods that will be discussed later in this dissertation.
Although the determination of gene clubs shares similarities with traditional feature
selection, it has some new characteristics and is based on the interaction among genes.

3.3. MICROARRAY DATA CONCORDANCE DETECTION
Microarray technology allows simultaneous measurements of mRNA expression of
thousands of genes. This technology provides the possibility of creating datasets that
capture the information concerning all the relevant genes and proteins for many systems
of biological or clinical interest. Such datasets are useful because they may help scientists
to discover gene interaction networks, and perhaps even pathways underlying various
diseases and biological processes. Such discoveries can in turn lead to better

19

understanding of the biological processes and diseases, and to better ways to diagnose
and treat diseases.
Recent advances in microarray technology have generated large amounts of gene
expression data, collected using a variety of commercial platforms from different
laboratories. The concordance/consistency of the datasets from different sources should
be evaluated before this technology can be successfully and reliably applied in
biological/clinical practice and regulatory decision-making (Shi et al., 2004, Hackett et
al., 2003, Petricoin et al., 2002b). This need was also recognized in recent publications
addressing some possible factors affecting the consistency of DNA microarrays (Guo et
al, 2006, Shi et al, 2006).
As mentioned in Section 2.2, two major factors, experimental noise and biological
variation may cause inconsistent results in repeated experiments during data generation in
microarray experiments. Experimental noise can be caused by differences in probe
labeling efficiency, RNA concentration or hybridization efficiency, image analysis and so
on. All types of such noise might make the experiments unrepeatable. As a result, the
expression levels reported by a microarray experiment might not exactly reflect the true
gene expression levels. Biological variation will be discussed in next section.
There has been wide interest in the intra- and inter-platform comparisons of gene
expression values (Kuo et al., 2002, Tan et al., 2003b, Hardiman, 2004, Shi et al., 2005,
Guo et al, 2006, Shi et al 2006). These studies reached different conclusions: On one
hand, some cross platform comparisons reported a failure to demonstrate an acceptable
level of correlation between different microarray technologies (Tan et al., 2003b,
Jarvinen et al., 2004, Woo et al., 2004, Yauk et al., 2004, Mah et al., 2004, Cicatiello et
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al., 2003, Marshall 2004); the authors conjectured that the difficulties in correlating data
may be attributed to fundamental differences between cDNA and oligonucleotide based
microarray technologies. Other studies concluded that low inter-platform consistency is
due to other reasons instead of inherent technical differences among different platforms
(Shi et al. 2005). Recent studies related to microarray quality control (MAQC) project
showed that the microarray data from different platforms are fairly concordant (Guo et al
2006, Shi et al 2006).
It is not easy to tell how concordant two datasets are. Different criteria (testing methods)
may give different answers. Most studies have focused on the expression values of
individual genes. They are not applicable for comparative studies, where one compares
one class of data against another class. Comparative microarray analysis can better
distinguish phenotypes from related phenotypes; identify valid differentially expressed
genes by combining many studies; test new hypothesis; and discover fundamental
patterns of gene regulation. In order to get reliable results when using comparative
methods, it is desirable to test the datasets’ concordance using the same comparative
methods.
The present work introduces novel comparative methods for evaluating concordance of
microarray data collected from different laboratories and/or different platforms. These
methods evaluate concordance by measuring quality preservation of discriminating genes
and classifiers. Considering that microarray datasets are generated from different
platforms, if the microarray datasets are concordant with each other with respect to
discriminating genes, then the knowledge on discriminating genes gained from one
platform/lab can be transferred to another platform/lab (Mao & Dong et al, in
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preparation).

3.4. BIOLOGICAL VARIATION
As mentioned in Section 2.2, two major factors: experimental noise and biological
variation, may cause inconsistent results in repeated experiments. Experimental noise can
arise at any step of microarray experiments. It might render the experiment nonreproducible. As a result, the expression levels reported by a microarray experiment
might not exactly reflect the true mRNA levels. Biological variation refers to the natural
variation we would expect to encounter even under ideal experimental conditions. In
other words, even if we could sidestep experimental issues, magically looking inside the
cells and counting the mRNA molecules of interest, we would still expect some variation
in counts between cells in the same category (Piatetsky_Shapiro et al, 2003).
Different from experimental noise, biological variation inevitably exists in microarray
dataset because of the variety among tissue samples (e.g. patients). Biological variation
may also affect the accuracy of data analysis and may lead to unreliable results. So far,
there are few, if any, studies to investigate how biological variability affects to data
mining results and how to reduce it in microarray dataset. Liu and colleagues (Liu et al,
2003) selected samples according to the patient’s surviving time. This selection can be
applied to some specific datasets but not to all microarray datasets.
In order to mine reliable patterns, the biological variability in microarray datasets needs
to be considered. In this study, first we investigate the influence of variability on our
comparative study and then we provide methods to minimize it.
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3.5. INSTANCE SELECTION
Instance selection aims to search for a representative data subset that replaces the original
dataset, still solving a data mining task as if the whole dataset were used. Finding a small
set of representative instances for large datasets can bring various benefits to data mining
practitioners (Zhu et al 2006): 1) build a learner superior to the one constructed from the
whole massive data; 2) avoid working on the whole original dataset all the time; and 3)
remove irrelevant instances as well as noise and/or redundant data. For most data mining
tasks, such as classification and clustering tasks, the selected dataset should preferably
exclude noisy instances. Many instance selection algorithms have been developed so far.
Sampling: Sampling, a basic instance selection, is a well established statistical technique

that selects a part from a whole to make inferences about the whole, which is applied to
overcome problems caused by high attribute dimensionality as well as large data volumes
in data mining. It can profitably used to estimate characteristics of a population of interest
with less cost, hihger speed, greater scope and probably greater accuracy compared to a
complete enumeration. It has been applied in different domains of real world application.
Many sampling-based algorithms have been proposed. According to their relations and
characteristics, these methods can be classified into different categories.
Genetic algorithm (GA) based instance selection: Genetic algorithms (Holland, 1975)

have been successfully applied to various problems (Goldberg, 1989). Genetic algorithm
can be viewed as a general-purpose optimization technique in discrete search spaces.
They are suitable for complex problems with multi-model objective functions. Their
application to instance selection was proposed by Kuncheva (Kuncheva, 1995) for
designing nearest neighbor classifiers. In her study, the classification performance of
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selected instances was maximized. A penalty term with respect to the number of selected
instances was added to the fitness function of her subsequent genetic algorithms
(Kuncheva, 1999). Later on, a generic algorithm-based approach was used for
simultaneously selecting instances and features (Liu, et al, 2001). Through computer
simulations, the authors demonstrated that a small number of instances can be
successfully selected together with only significant features by their genetic algorithm.
They also demonstrated that the generalization ability of nearest neighbor classifiers was
improved by the instance and feature selection in some datasets.
There are many other instance selection methods which are similar to those mentioned
above. These methods can reduce the number of instances in datasets, but they didn’t do
anything for the noise instance removal. The following methods consider how to detect
and eliminate the noisy instances.
Iterative case filtering algorithm: Iterative case filtering algorithm (ICF) was

introduced by Liu and colleagues (Liu et al, 2001). They improved the repeated Wilson
algorithm investigated by Tomek (Tmoek 1976) by applying a rule which identifies cases
that should be deleted. In the ICF algorithm, the authors built a K-Nearest-Neighbor
classifier, then found and removed the noisy instance which was wrongly predicted by
the k-NN classifier. This process is repeated iteratively until no more instances need to be
removed.
In all previous instance selection studies, few of them, if any, focused on microarray
dataset. In this study, we introduce a new instance selection method (C-loocv) by
improving ICF algorithm. C-loocv is applied to remove the noisy instance from
microarray datasets and more reliable data mining results are expected to be mined from
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the C-loocv refined datasets.

3.6. CLASSIFICATION
Classification aims to learn how to classify objects into one of a pre-specified set of
categories or classes. A robust classification method is very important to classify the new
samples into the correct category efficiently and accurately. There have been lots of
studies looking for reliable classification methods, as discussed below.
Naive Bayesian: Naive Bayesian is a simple probabilistic classifier based on Bayesian’

theorem with the (naive) independence assumption. Based on the rule, using the joint
probabilities of sample observations and classes, the algorithm attempts to estimate the
conditional probabilities of classes given an observation.
K-nearest neighbor (K-NN): K-NN is a method for classifying objects based on closest

training examples in the feature space, which is a type of instance-based learning where
the function is only approximated locally and all computation is deferred until
classification. The K-NN classifier is a simple supervised concept learning scheme which
classifies unseen instances by finding the closest previously observed instances, taking
note of their classes, and predicting the class for the unseen instance (Cover et al, 1967).
K-NN is a non-parametric classifier which has been applied to various information
retrieval problems. K-NN uses an integer parameter K. Given an input x, the algorithms
finds the K closest training data points to x, and predicts the label of x based on the vote
of labels of the K points.
Decision Tree: In data mining and machine learning, a decision tree is a predictive

model; that is, a mapping from observations about an object to conclusions about its
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target value. More descriptive names for such tree models are classification tree (discrete
outcome) or regression tree (continuous outcome). In these tree structures, leaves
represent classes and branches represent conjunctions of features that lead to those
classes. Thus, each node corresponds to a sequence of predicates and their values
appearing on the downward path from the root to it. Each leaf is labeled by a class. To
predict the class label of an input, a path to a leaf from the root is found depending on the
value of the predicate at each node that is visited.
Many classification methods have been derived from decision tree method. ID3 (Iterative
Dichotomiser 3) is an algorithm used to generate a decision tree (Quinlan 1993). It
prefers smaller decision trees (simpler theories) over larger ones. However, it does not
always produce the smallest tree, and is therefore a heuristic. The ID3 algorithm can be
summarized as follows: (1) Take all unused attributes and count their entropy concerning
test samples; (2) Choose attribute for which entropy is minimum; (3) Make node
containing that attribute.
C4.5 algorithm is an extended version of ID3, which is used to generate a decision

developed by Ross Quinlan (Quinlan 1993). C4.5 is often referred to as a statistical
classifier. C4.5 uses the fact that each attribute of the data can be used to make a decision
that splits the data into smaller subsets. C4.5 examines the normalized information gain
(difference in entropy) that results from choosing an attribute for splitting the data. The
attribute with the highest normalized information gain is the one used to make the
decision.
Committee decision techniques such as AdaBoost (Freund et al., 1996) and Bagging
(Breiman et al., 1996) have also been proposed to increase the prediction accuracy by
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voting the member decisions of the committee. Both AdaBoost and Bagging apply a base
classifier multiple times to generate a committee of classifiers using bootstrapped training
data. By the bagging idea, a bootstrapped training set is generated from the original data.
Boosting uses a different method to construct the committee of classifiers. It builds the
individual classifier sequentially so that every new classifier is influenced by the
performance of those built previously. Therefore, the samples incorrectly classified by
previous models can be emphasized in the new model.
Classification and Regression Tree (CART): CART (Breiman et al. 1984) are

nonparametric procedures for explaining and/or predicting a response, either categorical
(then this is discriminant analysis or classification), or continuous (then this is a
nonparametric regression).
Support vector machines (SVM): Support vector machines are a relatively new type of

learning algorithm. SVMs were originally introduced by Vapnik and co-workers (Boser
et al., 1992; Vapnik et al., 1998) and successively extended by a number of other
researchers (Malossini et al., 2000, Cristianini et al., 2000). Recently, SVMs have been
shown to perform well in multiple areas of biological analysis including evaluating
microarray expression data (Statnikov et al., 2005, Brown et al., 2000).
Support vector machines (Vapnik, 1998) have exhibited superb performance in binary
classification tasks. Intuitively, SVM aims at searching for a hyperplane that separates the
two classes of data with largest margin (the margin is the distance between the
hyperplane and the point closest to it). SVMs have demonstrated the ability to not only
correctly separate entities into appropriate classes, but also to identify instances whose
established classification is not supported by data. Although SVMs are relatively
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insensitive to the distribution of training examples in each class, they may still get stuck
when the class distribution is too skewed. This is obviously not the desired classification
result.
Emerging patterns (EPs): EPs (Dong, Li 1999) can also serve as a classification model.

By aggregating the differentiating power of EPs/JEPs, the constructed classification
systems (Li et al 2002, Li et al 2001, Dong, Zhang et al 1999) used to be more accurate
than other previously existing classifiers. In recent years, several new classifiers have
been generated on the basis of EPs, which will be discussed next.
Prediction by collective likelihood (PCL): PCL (Li, et al., 2002) is based on the

concept of emerging patterns. With the discovery of emerging patterns, PCL proceeds to
calculate a classification score for every class when a test sample is presented; and the
class with the highest score is predicted. The classification scores are calculated by
aggregating the frequencies of multiple top-ranked EPs: the committee of patterns and
their collective discriminating power show strong strength. This method makes higher
accuracy of prediction for many published microarray gene expression data (Li. et al.,
2003b).
Highly differentiative gene groups (HDGGs): Based on the previous studies, we

propose a new concept called HDGGs. HDGGs are the specific emerging patterns whose
frequency is the highest among the EPs mined from one gene club (Mao & Dong, 2005).
The classifiers built using HDGGs are called HDGG-based classifiers. Our experiments
indicate that such classifiers predict the samples in many microarray datasets with very
high accuracy. In this dissertation, we make considerable contribution for classification
problem using HDGG-based classifiers.
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Chapter 4: DISCOVERY AND APPLICATION OF
HIGHLY DIFFERENTIATIVE GENE GROUPS
(HDGGS)
4.1. MOTIVATION
It is commonly believed that suitable analysis of microarray gene expression profile data
can lead to better understanding of diseases, and better ways to diagnose and treat
diseases. To achieve those goals, it is of interest to discover the gene interaction networks,
and perhaps even pathways, underlying given diseases from microarray data.
Most physiological functions in human body are regulated by multiple genes instead of
individual genes. With specific diseases, the alteration of some physiological functions
may be controlled by a group of related genes which are interactive with each other. Such
groups of genes will be referred to as highly differentiative gene groups (HDGGs). Our
aim of this chapter is to give methods to find such groups of genes, from datasets
collected for studying such diseases.
We note that the discovery of HDGGs is a challenging problem, due to the high
dimensionality of microarray datasets.
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4.2. OUR APPROACH
A highly differentiative gene group (HDGG) is defined as a set of genes which coexpress in a certain manner consistently and frequently in the diseased class but never coexpress in that manner in the normal class, or vice versa. For example, in Table 4.1, {g4,
g5} is a HDGG since g4 is low (shown as ‘0’) and g5 is high (shown as ‘1’) in all diseased
samples, but there are no normal samples where g4 is low and g5 is high. We only want to
discover minimal HDGGs (in the set-containment sense) to ensure that the set of HDGGs
is concise. We use frequency of HDGGs in a class to measure their strength, where high
frequency indicates high strength. When a HDGG has 100% frequency in a class, we call
the HDGG a signature HDGG for that class.
Table 4.1 : A simple gene expression dataset
g1
g2
g3
g4
g5

d1
1
0
1
0
1

d2
0
0
1
0
1

d3
1
0
1
0
1

d4
1
1
1
0
1

d5
1
0
1
0
1

n1
0
1
1
1
0

n2
0
1
0
1
1

n3
0
1
1
0
0

n4
0
1
0
1
1

n5
0
0
1
0
0

d1…d5: diseased tissues; n1 … n5: normal tissues. g1 … g5: genes.
‘0’: the gene expresses low; ‘1’: the gene expresses high.
Since microarray data have thousands of dimensions, discovering HDGGs is a big
challenge. Border differential algorithm (Dong et al, 1999; Dong et al., 2005) is applied
to mine HDGGs. For HDGGs mining, the required search time is exponential in the
number of dimensions. Thus, exhaustive search of the whole dataset is impossible. The
border differential algorithm can effectively handle up to 75 genes for current generation
PCs, but can not finish in reasonable amount of time for much higher dimensions of
dataset. In this chapter, we introduce methods that can do much better job given the
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dimensionality challenge. Our methods are based on the novel concept of gene club.
A gene club is a set of genes in which the genes have high potential to be interactive with
each other. The total number of genes in a gene club should be big enough to contain
high frequency HDGGs; at the same time, it shouldn’t be too large for border differential
algorithm to effectively handle up under current generation PCs. Within in a gene club
we can (i) efficiently discover signature HDGGs which completely characterize the
diseased and the normal tissues respectively, (ii) find strongest or near strongest HDGGs
containing any given genes, and (iii) find much stronger HDGGs than using previous
methods.
The main idea of our approach is to select, for each given gene g, a set of genes which are
highly likely to be interactive with g. We call the set of potentially interactive genes a
gene club of gene g. We will consider several methods for finding good gene clubs.
Although the determination of gene clubs share similarities with feature selection, it has
some new characteristics and it is based on the interaction among genes.

4.3. GENE CLUB FORMATION STRATEGY
In this section, we discuss four methods for gene club formation: the independent method
(IN), the iterative method (IT), the divisive and independent method (DIN), and the
divisive and iterative method (DIT). Then, we show the results obtained from several
public microarray datasets and discuss the importance of mined HDGGs from the gene
clubs obtained using these methods.
Our gene club based methods work as follows: First, for each gene g we find a gene club
for some desired cardinality k. Second, we apply the border differential algorithm (Dong
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et al., 1999; Dong et al., 2005) to discover the best EPs containing g from the gene club.
Finally, we remove the conditions to get the HDGGs. All these methods utilize
information gain for gene groups.

4.3.1. Independent gene club formation
The independent gene club formation method (IN) forms a gene club for a gene g by
selecting the genes which are independently the most interactive with g. This method is
based on the notion of combined information gain, defined (for each gene g’) as

InfoGain ( g ' | g ) = InfoGain ( g , g ' ) − InfoGain ( g )
The combined information gain captures how g’ interacts with g with respect to the
disease under consideration, or how much “help” g’ offers to g w.r.t. the disease. The IN
method works by first ranking all genes g’ in decreasing InfoGain(g’| g) order, and then
selecting the k-1 genes g1, g 2, …, gk-1 with the highest combined information gain as the
gene club for g. Figure 4.1 illustrates how the method works; the combined information
gain is shown as the label for the edge from g to g’, apparently, I1 ≥ I2 ≥ … ≥ Ik-1.
From Table 2.1, the gene club of size 3 for gene g1 formed by IN consists of g2 and g4,
since InfoGain(g2|g 1) = 0.554 > InfoGain(g4|g 1) = 0.502 > InfoGain(gi|g1) for i = 3 or 5.

g

I1

g1

I2

Ik-1

…

g2

Figure 4.1: the IN method
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gk-1

4.3.2. Iterative gene club formation
The iterative gene club formation method (IT) forms a gene club for a gene g by selecting
the genes which are iteratively the most interactive with g for a current partial gene club.
This is different from the IN method, which does not consider the interaction of a new
gene with other selected genes. IT is based on the notion of generalized combined
information gain, defined (for each gene g’ and selected genes g1,…, gm) as
InfoGain( g ' | g1 , g 2 ... g m , g ) = InfoGain( g1 , g 2 ,... g m , g , g ' ) − InfoGain( g1 , g 2 ,... g m , g )
The generalized combined information gain captures how g’ interacts with the current
partial gene club with respect to the disease under consideration, or how much help g’
offers to the partial gene club w.r.t. the disease. IT finds a gene club of size k for g as
follows: First it sets the partial gene club to be {g}; it then selects the next gene g1 having
the highest InfoGain(g’ | g) among all remaining genes g’ and adds g1 to the partial gene
club; it then selects the next gene g2 having the highest InfoGain(g’| g1, g) among all
remaining genes g’ and adds g2 to the partial gene club; it then selects the next gene g3
having the highest InfoGain(g’| g1, g2, g) among all remaining genes g’ and add g3 to the
partial gene club; this process is repeated until the (k-1)th gene is selected and the partial
gene club becomes the final gene club of g. Figure 4.2 illustrates the iterative process,
where the edge labels represent the generalized combined information gain.

g

g

I1

g1

g

g1

I2

g2

g
g2

g1

I3

g3

…

Figure 4.2: the IT method

According to the data in Table 2.1, the gene club of g1 formed by IT consists of g2 and g5,
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which is different from that formed by IN. One can verify that InfoGain(g5| g2, g1) >
InfoGain(g4| g2, g 1).

4.3.3. Divisive gene club formation
We now turn to two more methods which first divide the data using a split value for g,
and then use one of the two previous methods to work with each partition. This is
illustrated in Figure 4.3. The selected genes from the two partitions are then combined to
form the overall gene club for g. If IN is used for each partition, this method is called the
divisive independent method (DIN); if iterative method is applied, this method is called
divisive iterative method (DIT).
g
Low

Hi

Independent
or iterative

Independent
or iterative

Figure 4.3 : the divisive method

We need to combine the genes selected from the two partitions. For both methods, we
first select 1/3 of the gene club members from each partition among genes with non-zero
information gain. The final 1/3 (or more if we did not get 1/3 in the last step) is chosen
from the remaining selected genes from the two partitions. In DIN, the last 1/3 is chosen
according to the information gain values for the genes from the two partitions. In DIT,
this is done by normalizing information gain using the partial gene club size.
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Normalization is used since it is not very meaningful to compare information gain over
gene groups with large size differences.

4.3.4. Converged gene ranking
Since there are thousands of genes in one dataset, it is impractical to establish gene clubs
for every single gene. A better strategy is to use top k ranked genes as seeds to form gene
clubs because the top ranked genes have stronger relationship with the specific class. In
each club, the HDGGs are mined with border differential algorithm.
As mentioned before, some genes may not be strongly related with the specific disease
individually, but they are very important for the disease under consideration when they
combine with other genes. In another word, they are important for the disease under gene
group based condition instead of individual condition. Therefore, we need to rank the
genes with new criterion which is based on genes’ participation in high-quality gene
groups.
Converged gene ranking is such a method that gives the genes which are involved in
HDGGs more frequently a higher rank. After the genes are ranked according to their
information gain, the converging method is applied to re-rank these genes. The following
is the algorithm for converged gene ranking:
(1). Ranking the genes in decreasing information gain order.
(2). Using all four gene club methods to obtain the high frequency HDGGs (using top
ranked genes as seeds). In each gene club, the HDGGs with the highest frequency are
chosen. H is the set of chosen HDGGs.
(3).Calculating the weight for every gene in each HDGG in H:
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Weight ( g ) =

∑ Frequency(g )

h : HDGG, H : set of HDGGs

g∈h , h∈Η

(4). Re-ranking the genes according to their weight.
(5). Repeating steps (1) to (4) until the gene rank order reaches steady state.
As will be seen later, the set of top ranked genes using information gain gene ranking
method are different from that using converged gene ranking method. Therefore, the
seeds for gene club formation are also different. With converged gene ranking, we
discover many high frequency HDGGs which are missed by information gain gene
ranking method. Therefore, this strategy can be considered as an auxiliary method which
can help to find higher frequency HDGGs from microarray datasets.

4.4. BUILDING HIGH ACCURACY HDGG-BASED CLASSIFIERS
HDGGs can also be used to build classifiers to diagnose diseases with very high accuracy.
The following pseudo-code describes how to build HDGG-based classifiers. (The
parameter k can be determined by the user based on the available computation power. In
this research, we choose k = 20 as its default value unless stated otherwise). The details
on building HDGG-based classifier can be found in Chapter 6.
1. Find the top k genes g1, …, gk ranked by information gain;
2. For each gene gi, find its gene club using the IT method, and then find the strongest
HDGGs containing gi using border differential algorithm;
3. Among the mined HDGGs, a total of 2 * k HDGGs are chosen as classifier according
to our criteria (see below). Among all these chosen HDGGs, k HDGGs are from one
class whereas the other k HDGGs from the other class;
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4. For a given test sample T, T’s score in class x(Cx) is calculated according to the
frequency of each chosen HDGGs in Cx:

S (T ) _ C x =

in C )
∑ frequency(HDGG
n
k

i

i =1

x

x

where n x is the total number of samples in Cx.
By comparing the scores of T in all classes, T is categorized into the class in which T has
the highest score.

Criteria for choosing HDGGs: We apply border differential algorithm to obtain plenty

of HDGGs from gene clubs. Among them, we need to choose the typical HDGGs as
classifier according to following criteria:
(1) High HDGG’s frequency, the higher the better. This is the most important one.
(2) Low gene overlapping in the chosen HDGGs, the lower the better. This strategy is
called gene diversity.
(3) Tie breaking. Two or more HDGGs may have the same frequency and same gene
diversity. We need to make a rule to break the tie. The following are our rules:
(i). Comparing the length of each HDGG, shorter HDGGs ranks higher;
(ii). Comparing the gene’s rank between two or more equivalent HDGGs, the HDGGs
which contain the lowest ranked gene should be ranked lower. This is also called
“smallest first rule”. For example, two HDGGs {1, 3, 5} and {2, 3, 4}, both have the
same length of three genes, gene ‘4’ ranks higher than gene ‘5’, so HDGG {2, 3, 4} ranks
higher than {1, 3, 5}.
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4.5. RESULTS AND EVALUATION
We evaluate the effectiveness of our methods in terms of (i) the high-strength HDGGs
discovered, (ii) the ability to find the strongest HDGGs, (iii) the improvement of strength
of discovered HDGGs over the top-k gene method, and (iv) the meaningful biological
functions of our HDGGs compared with previous gene group methods. The experiments
were conducted on the following datasets: (1) colon cancer data (Alon et al., 1996),
which has 2000 genes and 62 tissue samples (22 normal ones and 40 cancer ones); (2)
prostate cancer data (Singh et al., 2002), which has 12600 genes and 102 tissue samples
(50 normal ones and 52 cancer ones); (3) breast cancer data (van’t Veer et al 2002),
which has 24481 genes and 78 tissue samples (44 non-relapse ones and 34 relapse ones);
(4) ovarian cancer data (Petricoin et al 2002a), which has 15154 genes and 253 tissue
samples (91 normal ones and 162 tumor ones); (5) leukemia data (Golub, 1999), which
has 7129 genes and 72 tissue samples (47 ALL and 25 AML).

4.5.1. High strength HDGGs
Table 4.2 lists the top 10 HDGGs and EPs in diseased tissues and normal tissues for the
colon cancer data. The HDGGs can be obtained by removing the high/low signs from the
EPs. Each number represents a gene, with ‘1’ for the highest ranked gene according to
the information gain order. The signs of ‘+’ and ‘–’ represent “high” and “low”
respectively, e.g. ‘1+’ is for “gene 1 is high”, and ‘4-’ is for “gene 4 is low”. We give the
accession number and description for the genes which occur in the HDGGs, and their
split values in Table 4.8.
We observe that some of the signature HDGGs involves genes ranked at 1089. This
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implies that such genes are very weak for characterizing the cancer by themselves, but
they can completely characterize the cancer when combined with several other genes.
Table 4.2: The top 10 HDGGs in diseased (left) and normal tissues (right) of colon data
Count

Frequency
(%)

{1+ 4- 112+ 113+}

40

100

{1+ 4- 113+ 116+}

40

100

{1+ 4- 113+ 221+}
{1+ 4- 113+ 696+}
{1+ 108- 112+ 113+}
{1+ 108- 113+ 116+}
{4- 108- 112+ 113+}
{4- 109+ 113+ 700+}
{4- 110+ 112+ 113+}
{4- 112+ 113+ 700+}

40
40
40
40
40
40
40
40

100
100
100
100
100
100
100
100

Emerging patterns

Emerging patterns
{12- 21- 35+ 40+ 137+
254+}
{12- 35+ 40+ 71- 137+
254+}
{20- 21- 35+ 137+ 254+}
{20- 35+ 71- 137+ 254+}
{5- 35+ 137+ 177+}
{5- 35+ 137+ 254+}
{5- 35+ 137+ 419-}
{5- 137+ 177+ 309+}
{5- 137+ 254+ 309+}
{7- 21- 33+ 35+ 69+}

Count

Frequency
(%)

22

100

22

100

22
22
21
21
21
21
21
21

100
100
95.5
95.5
95.5
95.5
95.5
95.5

4.5.2. Ability to find top strength HDGGs and improvement of strength
over top k method
Experiments showed that our methods can often find the strongest HDGGs, and they can
find EPs whose frequency is very close to the strongest for cases when our methods
cannot find the strongest EPs. The experiments are set up as follows: From the colon
cancer data, we picked the top 75 genes under the information gain rank. (The number 75
is chosen for reasons discussed in section 4.2) We then use the border differential
algorithm to exhaustively mine all the EPs in these 75 genes. For each g of these 75
genes, let SupBEP(g) be the highest frequency (support) of the discovered EPs containing
g. We then apply the four methods introduced in this chapter, together with the top-k
method, on these 75 genes, using a gene club size of 20. For each gene g, we check
whether a given method can find an EP containing g with frequency of SupBEP(g) from
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the 75 genes. We considered how often each of the methods is able to find the strongest
EP.
We first let S consist of the top 75 genes ranked by information gain. The IT method is
the best, which can find the strongest EPs for about 82.5% of the genes. We also found
that the average frequency (over the 75 genes) of the strongest EPs found by IT is more
than 98% of the average support of the strongest EPs. In contrast, the top-k method can
only find the strongest EPs for 32.5% of the genes, and the average frequency of the
strongest EPs found by that method is about 77% of the average frequency of the
strongest EPs. The other three of the new methods are slightly worse than IT. Figure 4.4
shows the performance of all methods in terms of the average frequency of the strongest
EPs for the top 20 genes. In the figure, EX denotes the exhaustive method, and GT20
denotes the top-k method with k = 20.
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0.7
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2 GT20
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4 DIN
5 IT
6 DIT
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2
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6

Figure 4.4: Average frequency of strongest EPs found by six methods over top 75 genes
in colon cancer data

The experiments over randomly selected sets of 75 genes also showed similar
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performance. Experiments reported in Figure 4.4 show that the new methods improve
over the top-k method by a large margin. Indeed, the IT method improved the average
frequency by 47.1% and 29.8% respectively, in diseased tissues and normal tissues, over
the top-k method.
We also conducted experiments for gene club size of 35. Every method except EX
improved. The relative performance of the methods is similar to the case when the gene
club size is 20.

4.5.3. From HDGGs to gene functions and disease understanding
By using our HDGGs based method to group genes, we found that many genes in the
HDGGs are related to the disease under consideration (i.e. colon cancer in our example).
Indeed, from the signature HDGGs in Table 4.2, we found several genes have known
biological functions. For example, in the HDGG {1, 4, 112, 113}, gene 1 (Chang et al.,
2002) has been studied intensively. It is one of the major mediators of the inflammatory
response and a potent angiogenic factor. There is a close relation between the level of this
gene and the state of illness: the higher the expression level it is, the more serious the
patients' condition. Gene 4 encodes a kind of cysteine and glycine-rich protein, which
may be involved in regulatory processes important for cellular development and
differentiation (Wang et al., 1992). Gene 112 regulates cell growth; it is believed to have
some tissue-specific functions, although its specific function is still under study (Nomura
et al., 1994). Gene 113’s function includes the following: it accelerates differentiation of
select human hematopoietic cells; it encodes a protein which is a receptor in
erythropoiesis; it may play a role in angiogenesis (Wang et al., 2002). The fact that {1+,
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4-, 112+, 113+} is a pattern characterizing the colon diseased tissue is consistent with the
function of the four involved genes.
Some genes in HDGGs, especially the low-ranked genes, have not received enough
investigation. The membership of these genes in HDGGs indicates that these genes are
important for the disease under consideration. For example, gene 113, gene 216, gene
1089 and so on are low-ranked genes. We were not able to find definitive published
results indicating the function of such genes. We believe that these genes should be
studied further in the biology and medicine fields.
The HDGGs may be used to suggest research directions to find gene functions and to
discover new pathways. Many of the cancers considered in this paper are still the subject
of extensive research (Sugiyama et al 2005), and the majority of the pathways are still to
be found in large NIH supported projects (Newcomb 2003). These may be reasons why
we only found the APC pathway related to colon cancer in the literature and the web, and
the APC gene (accession number M74088) for this pathway was not included in the colon
cancer data.
We also observed that, for some diseases such as leukemia and lung cancer, our gene
club methods produced smaller improvement over the top-k approach than for other
diseases. This happened because the top-k approach has achieved very high average
support (89% in leukemia and 94% in lung cancer data) already – there is little room for
further improvement. Interestingly, this implies that the important gene groups for these
diseases only involve top ranked genes under the entropy measure. We suggest that this
might be used as an indication that these diseases have relatively low disease complexity.
On the other hand, colon and prostate cancers may have high disease complexity, since
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there are important gene groups for these diseases that involve genes that are ranked quite
low under the entropy measure.

4.5.4. Other datasets
We also conducted experiments on several other datasets. The results are mostly similar
to that for the colon cancer data. For the prostate data, the improvement of the IT method
over the top-k method is 16.97% in diseased tissues and 35.99% in normal tissues,
respectively (see Figure 4.5). We list some of the top HDGGs in Table 4.7. For the breast
cancer data, the improvement of the IT method over the top-k method is 6.03% and
14.55% respectively (see Figure 4.6). For the ovarian data, the improvement is 4.41% and
0.92% respectively (see Figure 4.7).
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Figure 4.5: Average frequency of strongest EPs by different methods for prostate data

43

0.8

Average Support

Relapse
Non-relapse

0.7

x-axis
meaning:
1 GT20
2 IN
3 DIN
4 IT
5 DIT

0.6

0.5
1

2

3

4

5

Figure 4.6: Average frequency of strongest EPs by different methods for breast cancer
data
0.96

Cancer tissue

Average Support

0.94

Normal tissue

0.92
x-axis
meaning:
1 GT20
2 IN
3 DIN
4 IT
5 DIT

0.9

0.88
1

2

3

4

5

Figure 4.7: Average frequency of strongest EPs by different methods for ovarian data

4.5.5. Gene ranking by converged method
We re-ranked the gene by using HDGG-converged method. On average, most datasets
can reach converged stage within 10 - 20 cycles. Table 4.3 lists the sets of top 20genes
ranked by information gain and by converged gene ranking method using colon cancer
data.
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Table 4.3: Top 20 genes using information gain ranking and converged ranking

Ranking order Information gain ranking Converged gene ranking
1
1670
1422
2
681
248
3
575
492
4
764
1670
5
1771
1041
6
1923
624
7
1041
1581
8
1422
624
9
512
1632
10
1770
174
11
244
1634
12
257
764
13
779
1559
14
398
257
15
896
1885
16
1581
492
17
1292
248
18
651
580
19
1226
1327
20
42
398

In the table, the first column is the gene rank order; the second column is the information
gain based ranking result and the third column is the result by gene converged ranking
method. The number in the table is the gene’s index. We notice that 50% of top 20 genes
of the two methods are different. We use bold-number to mark the shared genes (in both
top 20 genes of the two methods). The converged ranking is gene group-based, whereas
information gain ranking is individual gene-based. The experimental results show that
some important genes for one class are not the top genes in the individual gene based
rank.
In colon cancer dataset, the average frequency of top 20 HDGGs obtained by information
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gain ranking is 71.4% whereas that from converged gene ranking is 89.4%. The average
frequency increased 18%. Using other microarray gene expression data to compare these
two ranking methods, we also observed that the average frequency increases in some
degree (data not shown).

4.5.6. Comparison of HDGGs based classification method with other
methods
In this section, we compare our HDGGs-based classifier with other classifiers for
predicting several published microarray cancer datasets. For a given dataset, if one
classifier can predict the samples with lower error rate, we say that classifier is more
robust. The error rate of a classifier is defined as the number of samples in a dataset that
are incorrectly predicted by the classifier. It is also called test error rate, which is widely
used in biomedical fields.
Table 4.4: The error rates of six classification algorithms

Datasets
Ovarian
Lung Cancer
ALL subtypes

HDGGs PCL SVM
3.4
2
4

4
3
4

5
1
7

C4.5
Boosting Bagging Single
5
8
10
27
18
27
14
10
21

Using three public datasets (Ovarian, Lung cancer (Hong et al, 1991) and ALL subtypes)
which have been partitioned into training and testing sets already, we directly compare
the classification results produced by our methods and some existing classification
algorithms. Our method (HDGGs-based) has lower error rate than other algorithms
(Table 4.4). The numbers shown in the table are the error rate. There is no testing data in
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ovarian cancer data, so we used 10-fold cross validation method to estimate the error rate.
We repeated the 10-fold cross validation method for 10 times, and then got the average of
error rates for ovarian dataset. Our results indicate that HDGGs can be used to build very
good classifiers and HDGGs are very important feature for a dataset.

4.6. DISCUSSION OF HDGGS AND FUTURE WORK
Some other methods do not work for HDGG mining : Since frequent itemsets are anti-

monotone (i.e. all subsets of a frequent itemset are frequent), one may be tempted to think
that some frequent-item or frequent-itemset based methods can be used to efficiently find
the high-frequency EPs and HDGGs. For example, one may remove all the non-frequent
items and then mine the reduced data set. For example, suppose that we want to find EPs
whose frequency is at least 70% in the diseased tissues. We can first find the frequent
items whose frequency is ≥ 70% in the diseased tissues. Then, for each tissue (sample),
we remove the non-frequent items. The reduced samples will then be used to do border
differential against the normal tissues.
Table 4.5: Minimum, maximum and average tuple length in reduced dataset of colon
data

Threshold
%
100
90
80
70
60
50

Diseased class
Normal class
Min Max Avg Min Max Avg
179 179 179 541 541 541
423 534 510 730 835 820
596 943 864 863 1051 1010
705 1196 1075 912 1220 1147
795 1364 1216 982 1362 1267
868 1491 1322 1107 1494 1395

This method will not work for microarray gene expression data, because the reduced data
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sets will still have very high dimensionality. Table 4.5 lists the maximum, minimum, and
average length of the reduced tuples for thresholds ranging from 50% to 100%. Observe
that, even for the threshold of 100%, the average tuple lengths are still 179 and 541 in the
diseased and normal classes, respectively. Moreover, the method is not desirable since it
requires the user to give a threshold.
Duplicated genes: There are thousands of gene probes in one microarray chip. During

hybridization reaction, many different gene probes may hybridize with one gene
sequence. These gene probes are called duplicate gene probes though their sequences are
different. In our data analysis, we only keep one copy and eliminate the rests before gene
club formation among all duplicated probes.
The following is our criteria for identifying duplicate (or equivalent) genes: We consider
two genes g1 and g2 as duplicate genes if (a) InfoGain(g1 | g2) = InfoGain(g2 | g1) = 0, and
(b) NormMutualInfo(g1, g 2) = 100%, where NormMutualInfo = (Entropy(g1) +
Entropy(g2) – Entropy(g1, g2)) / max (Entropy(g1), Entropy(g2)).
In the colon cancer dataset, there are 106 genes which have duplicated copies, and the
total number of duplicated copies is 449 (so 343 of these are removed). Table 4.6 lists the
duplicated genes among the top 500 genes in colon cancer data (Alon et al., 1996). Each
row contains a set of genes which are equivalent to each other.
Table 4.6: Duplicated genes in top 500 gene group of colon data

11
112
168
369
371
376
378
382

12
117
169 170 171
373 375 377 380 385 394 395 402
401
387 388 391
400
383
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Disease complexity: We also observe that, for some diseases such as leukemia and lung

cancer, our gene club methods produce smaller improvement over the top-k approach
than for other diseases. This happens because the top-k approach has achieved very high
average frequency (89% in leukemia and 94% in lung cancer data) already – there is little
room for further improvement. Interestingly, this implies that the important gene groups
for these diseases only involve top ranked genes under the entropy measure. We suggest
that this might be used as an indication that these diseases have relatively low disease
complexity. On the other hand, colon and prostate cancers may have high disease
complexity, since there are important gene groups for these diseases that involve genes
that are ranked quite low under the entropy measure.

Limitation: It is commonly known that microarray datasets are highly variable. The high

variability in microarray data may affect the reliability of the discovered HDGGs.
Therefore, it is necessary to test the effect of variability on our data mining results. In
Chapters 5-7, we are going to investigate and minimize the effect of variability, and mine
reliable HDGGs from highly variable microarray datasets.

4.7. APPENDIX
Table 4.7 lists the top HDGGs in normal and diseased classes in prostate cancer dataset
(Singh et al., 2002). There are 52 disease samples and 50 normal samples in this dataset.
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Table 4.7 : The top 10 HDGGs in diseased (left) and normal tissues (right) of prostate
cancer data
Emerging patterns
{07- 331- 557+ 5011-}
{07- 331- 564+ 5011-}
{07- 331- 708+ 5011-}
{07- 331- 719- 5011-}
{07- 557- 657- 5011-}
{07- 564+ 657- 713+ 5011-}
{07- 657- 708+ 5011- }
{07- 657- 719- 5011-}
{01- 947- 1271-}
{01- 1271- 2083-}

Count
51
51
51
51
51
51
51
51
50
50

Support
(%)
98.1
98.1
98.1
98.1
98.1
98.1
98.1
98.1
96.1
96.1

Emerging patterns
{11- 19- 20+ 41+}
{11- 20+ 41+ 3890+}
{11- 20+ 41+ 122-}
{11- 41+ 78-}
{19- 41+ 78- 122-}
{01+ 06- 2002+}
{04- 11- 19- 41+}
{04- 11- 41+ 122-}
{04- 11- 41+ 3890+}
{04- 18+ 507+ 1937+}

Count
43
43
43
43
43
42
42
42
42
42

Support
(%)
86
86
86
86
86
84
84
84
84
84

Table 4.8 is the description of the genes that are involved in HDGGs in colon cancer data.
We named the genes that are involved in HDGGs discriminating genes (DGs).
Table 4.8: Description of genes involved in HDGGs in Table 4.2

Gene Splitting Accession
Description
number
number
point
1
59.83
M26383 monocyte-derived neutrophil-activating protein mRNA
2
1696
M63391 Human desmin gene
3
379.4
R87126 MYOSIN HEAVY CHAIN, NONMUSCLE (Gallus
gallus)
4
842.3
M76378 Human cysteine-rich protein (CRP) gene, exons 5 an
exon 6
5
84.88
H08393 COLLAGEN ALPHA 2(XI) CHAIN (Homo sapiens)
6
230
X12671 Heterogeneous nuclear ribonucleoprotein (hnRNP) core
protein A1
7
275
R36977 TRANSCRIPTION FACTOR IIIA
8
735.8
J02854
MYOSIN REGULATORY LIGHT CHAIN 2
9
447
M22382 MITOCHONDRIAL MATRIX PROTEIN P1
10
88.9
J05032
Human aspartyl-tRNA synthetase alpha-2 subunit
mRNA
11
1048
M76378 Human cysteine-rich protein (CRP) gene, exons 5 and 6
12
390.4
M16937 Human homeo box c1 protein, mRNA
13
400
H40095 MACROPHAGE MIGRATION INHIBITORY
14
289
U30825 Human splicing factor SRp30c mRNA
15
334
H43887 COMPLEMENT FACTOR D PRECURSOR
16
84.2
H51015 H.sapiens mRNA for p cadherin
17
417.3
X57206 GTP-BINDING NUCLEAR PROTEIN RAN
50

18
19
20
21
35
40
69

494.2
75.43
2598
735.6
58.51
356.4
97.4

R10066
T96873
T57619
R84411
M36634
R28373
R39209

71
108
109

454.7
3239
282.3

H17434
Z24727
J03040

110
112
113

123.6
99.38
155.5

K03460
D14812
T51849

116

24.29

R49459

117

36.63

H49515

136

189.2

X61118

137
177
188
216
254

26.81
24.6
147.5
31
29.03

R06601
T40578
M31303
H66786
H64807

263
309

373.3
1393

M69135
H20709

696

126.4

M59807

700

116.5

H87465

1089

373.5

R80855

1261

81.16

M23254

PROHIBITIN (Homo sapiens)
HYPOTHETICAL PROTEIN IN TRPE 3'REGION
40S RIBOSOMAL PROTEIN S6 (Nicotiana tabacum)
SMALL NUCLEAR RIBONUCLEOPROTEIN
Human vasoactive intestinal peptide (VIP) mRNA
HEMOGLOBIN BETA CHAIN (HUMAN)
IMMUNODEFICIENCY VIRUS TYPE I ENHANCERBINDING PROTEIN 2
NUCLEOLIN (HUMAN)
H.sapiens tropomyosin isoform mRNA, complete CDS
SPARC PRECURSOR (HUMAN);contains MSR1
repetitive element
Human alpha-tubulin isotype H2-alpha gene, last exon
Human mRNA for ORF
TYROSINE-PROTEIN KINASE RECEPTOR ELK
PRECURSOR
TRANSFERRIN RECEPTOR PROTEIN (Homo
sapiens)
SIGNAL RECOGNITION PARTICLE 68 KD
PROTEIN
Human TTG-2 mRNA for a cysteine rich protein with
LIM motif
METALLOTHIONEIN-II (Homo sapiens)
40S RIBOSOMAL PROTEIN S6 (Homo sapiens)
Human oncoprotein 18 (Op18) gene
ESTROGEN SULFOTRANSFERASE (Bos Taurus)
PLACENTAL FOLATE TRANSPORTER (Homo
sapiens)
Human monoamine oxidase B (MAOB) gene, exon 15
MYOSIN LIGHT CHAIN ALKALI, SMOOTHMUSCLE ISOFORM
NATURAL KILLER CELLS PROTEIN 4
PRECURSOR
PRE-MRNA SPLICING FACTOR SRP75 (Homo
sapiens)
MAJOR HISTOCOMPATIBILITY COMPLEX
ENHANCER-BINDING PROTEIN MAD3
Human Ca2-activated neutral protease large subunit
(CANP) mRNA
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Chapter 5: MICROARRAY GENE EXPRESSION
DATA CONCORDANCE DETECTION
5.1. MOTIVATION
The microarray technology has great potential for improving our understanding of
biological processes, medical conditions and diseases. Often, microarray datasets are
collected using different microarray platforms (provided by different companies) under
different conditions in different laboratories. The cross-platform and cross-lab
concordance of the microarray technology needs to be evaluated before it can be
successfully and reliably applied in biological/clinical practice.
It has been realized that different testing methods may cause different concordance
results. In previous studies, the cross platform and cross lab concordance of microarray
data has been tested using statistical methods, but not with comparative study yet. In this
chapter, we will detect the cross platform and cross lab concordance under the
comparative perspective.

5.2. OUR APPROACH
In this chapter, we introduce novel comparative methods for evaluating concordance of
microarray data collected from different platforms and different laboratories. Our
methods evaluate this concordance by measuring quality preservation of discriminating
genes and classifiers. The discriminating genes are the genes that participate in HDGGs,
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and the classifiers are the HDGG-based classifiers which have been discussed in Chapter
4. They are used to test the platform/lab concordance under the comparative perspective.
Our rationale for classifier/discriminating gene transferability is: Considering that
microarray datasets are generated from different platforms, if the microarray datasets are
concordant with each other with respect to discriminating genes or HDGG based
classifiers, then the knowledge on discriminating genes/HDGG based classifiers gained
from one platform/lab can be transferred to another platform/lab. This is called
classifier/discriminating gene transferability.
We apply classifier transferability to test the degree of classifier-based concordance
between different platforms/laboratories; we use consistency rate to detect concordance
(consistency) between the datasets before and after most of the gene-level noise is
removed; and we also use P-value to quantitatively measure the concordance between
platforms/laboratories. Conclusions on concordance based on our methods mostly agree
with previous conclusions obtained using other methods, except the cases involving one
particular platform. It should be noted that our methods are very general, and can be
applied when two or more tissue types/classes are available.

5.3. MATERIALS AND METHODS
5.3.1 Gene expression data
In this chapter, we evaluate our methodology by using some microarray gene expression
data provided by the Microarray Quality Control (MAQC) project in terms of inter-lab
and cross-platform concordance. We describe the MAQC data briefly below; more details
can be found in MAQC main paper (Shi et al., 2006). The datasets were generated using
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more than 10 different platforms in more than 30 different labs. We use the data
generated using four major platforms (Applied Biosystem(ABI), Affymetrix(AFX),
Agilent on color array (AG1), and GE Healthcare(GEH)), leading to a total of 12 datasets.
Among them, AG1 is a fairly new technology compared with the traditional two color
Agilent platform.
For each platform, there are three repeated datasets (explained below), each from one of
three laboratories; this design makes both inter/intra platform comparison possible. More
specifically, four standard mRNAs are used in each lab/platform combination, which
implies that biological variation has been eliminated. The four mRNAs are named as A,
B, C (75%A + 25%B) and D (25%A + 75%B). mRNA A is the universal human
reference RNA (SUHRR) provided by the Stratagene; and mRNA B is the ambion human
brain reference RNA (AHBRR) from the Ambion. While mRNA A and B are primitive,
mRNA C and D are mixtures of A and B with the proportions given above. In each
dataset, there are five repeats for each mRNA, giving rise to a total of 20 chip data. Since
C contains more A than B whereas D contains more B than A, mRNA A & C are grouped
into one class, whereas mRNA B & D into the other class; Table 5.1 gives a schematic
explanation. This division is used in all datasets.
Table 5.1: MAQC style dataset structure

Class 1
Class 2
mRNA A
mRNA C
mRNA B
mRNA D
t1 . . . t5 t6 . . . t10 t11 . . . t15 t16 . . . t20
g1
…
gn
One MAQC dataset: g1..gn are genes; t1…t20 are tissues;
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The concordance among laboratories/platforms is tested by comparing the datasets
generated from these lab-platform combinations. Observe that, all of the datasets from a
common platform have the same set of genes and RNA samples, and they use the same
gene IDs and RNA sample IDs to refer to the genes and samples. For datasets generated
from different platforms, the same samples are used but they may use different sets of
genes.

5.3.2. Discovery of discriminating genes
One main idea in this chapter is to use the transferability of discriminating genes from
one dataset to another to evaluate the concordance of two given datasets. Discriminating
genes are genes which are highly correlated with a class, or genes which participate in
highly differentiative gene groups (HDGGs). The discriminating genes are transferable
from one lab/platform combination to another, if the discriminating genes discovered
from the dataset generated from the first lab/platform combination are highly likely also
discriminating genes for the dataset generated by the second combination, and vice versa.
Intuitively speaking, high discriminating-gene transferability implies that one can use
discriminative knowledge gained in one platform/lab combination in another platform/lab
combination. In this chapter, we use discriminating patterns that occur in one class but
never occur in the other class. Such discriminating patterns are referred to as HDGGs
(Mao & Dong 2005) in data mining studies. HDGGs have been proved to be very useful
for discovering the inherent distinctions between different classes of data, and they have
been very useful for building highly accurate classifiers (see Chapter 4).
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The MAQC data we use have only 20 samples. A very high proportion of HDGGs mined
from such data contain only one gene. Thus, the HDGGs from MAQC data can be
considered to be equivalent to highly frequent jumping EPs (JEP), which are defined as
emerging patterns that appear in one class but never exist in other classes.
As mentioned in Chapter 4, the genes which are involved in HDGGs (or highly frequent
JEPs) are considered as discriminating genes. If a JEP involves just one gene, then the
JEP has a condition of one of the following two forms: “g ≤ v” or “g > v”, where g is a
gene and v is a value; the condition asks whether gene g’s expression value (in a tissue
under consideration) is ≤ or > than v. A multi-gene JEP is a set (or conjunction) of
several such conditions; we refer to a JEP with k conditions as a k-gene JEP. Multi-gene
JEPs capture interactions among genes which only happen in one class but never in the
other classes. Since many biological functions are regulated by multiple genes, we
collected the DGs from 2-gene and 3-gene JEPs, besides those from one-gene JEPs. After
using the entropy-based method (Dougherty et al., 1995) to find the split value for each
gene, the so-called “iterative gene club formation algorithm” (Mao & Dong, 2005) was
employed to discover 2-gene and 3-gene JEPs from the two classes of each MAQC
microarray dataset. We selected the JEPs having 100% frequency in the class they occur,
so the discriminating genes in such JEPs are frequently involved in discriminative
interactions among genes.
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5.3.3. Classifier transferability
If a classifier built from the two classes in one dataset is applied to predict the sample’s
class type in another dataset and the prediction accuracy is high, and vice versa, the
classifiers can be transferred between the two datasets. High classifier transferability
represents high similarity between the two datasets. Since MAQC datasets were derived
from different labs/platforms, high classifier transferability between pairs of such datasets
indicates high concordance among these labs/platforms. Thus, classifier transferability is
a good criterion to test the platforms’ concordance. Intuitively speaking, high classifier
transferability implies that one can use diagnosis knowledge gained in one platform/lab
condition to predict what may be happening in another platform/lab condition.
A classifier is a function (or computer program) for classifying objects without class label
to one of a pre-specified set of categories or classes. It is trained from data having class
labels. In terms of microarray data, the goal is to build highly accurate classifiers that
may be used to predict class membership for new microarray samples. Some selected sets
of emerging patterns have been used as classifiers to predict new samples in microarray
data with considerable predicting accuracy (Li, J et al., 2002, Li, Dong et al., 2001, Dong
et al., 1999). Therefore, JEPs can also act as very good classifiers to test classifier
transferability.
Here, discriminating genes (DGs) gathered from one-gene jumping emerging patterns
(JEP) were exploited as classifier to check the classifier transferability between any given
dataset pair. We used the DGs to build a voting classifier as follows: For each
discriminating gene gi, suppose ui is gi's split value such that “gi θ ui” is a one-gene JEP
(where θ is either ≤ or >), and suppose C1 and C2 are respectively the majority classes of
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gi's low/high intervals. Then gi can be used as a low-level classifier as follows: for an
arbitrary tissue T, if T(gi) < u i, then T is predicted to be member of C1; otherwise, T is
predicted as member of C2. We now have a low-level classifier for each of the DGs. The
voting classifier’s final decision of T’s membership is reached by the voting result of all
of the DGs.
In assessing classifier transferability, for each dataset D (or lab/platform combination) we
get the discriminating genes as a classifier. Then we test the classifier on any other
dataset D’. We use the accuracy of the classifier on D’ as the numerical measure for
classifier transferability.

5.3.4. Discretized-bin consistency rate between dataset pair
We also propose another concept called discretized bin consistency rate, or consistency
rate (CR) to measure the concordance between (datasets generated from different)
laboratories/platforms. The CR between a given pair of datasets is defined as the
percentage of binary bits (interval values, where each interval is a bin in entropy-based
discretization (Dougherty et al., 1995) for the two classes in a given dataset) whose values
are consistent between the two datasets. For example, in Table 5.2, there are 4 tissues and
3 genes in each of the datasets D and D’. g2’s expression value in t3 is “0” in D but it is
“1” in D’. This is the only inconsistency between D and D’; all other corresponding bits
in matching tissues for matching genes are consistent. The total number of bits in each
dataset is 4 * 3 = 12, and the number of inconsistent bits is 1. So the consistency rate
between this dataset pair is 11/12 = 91.7%.
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Table 5.2: Discretized microarray dataset pair (D & D’) sample

D
g1
g2
g3

t1
0
1
0

t2
0
1
0

D’
t3
1
0
1

t4
1
0
1

t1
0
1
0

t2
0
1
0

t3
1
1
1

t4
1
0
1

t1…t4: tissues; g1 … g3: genes; ‘0’: the gene expresses low; ‘1’: the gene expresses high.

As mentioned earlier, discriminating genes have been proven to be of great importance,
because they contain the most valuable information for classification in each specific
dataset. Our hypothesis is that working on the discriminating genes may give us more
accurate as well as useful results for analyzing the relationship between different datasets.
On the other hand, the expression value of non-discriminating genes may be inherently
random for biological reasons, and is unimportant or less important for most
medical/biological studies. When used in concordance analysis, the non-discriminating
genes may contribute a large proportion of inconsistency. In this study, two methods of
calculating the consistency rate between a dataset pair are performed and compared, (1)
one using all genes while (2) the other one using the discriminating genes only.

5.3.5. Calculation of P-value
Another criterion to check cross lab/platform concordance is P-value; P-value is used to
measure how much evidence we have against the null hypotheses (which states that there
is no difference between two given datasets). Small P-values suggest that the null
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hypothesis is unlikely to be true. Traditionally, researchers will reject a hypothesis if the
P-value is less than 0.05. Here, the P-value is supposed to quantitatively show how
similar two given datasets are. If P-value is less than 0.05, the two datasets are considered
as coming from different populations, i.e. they are not concordant with each other. We
calculate the P-value by using the permutation test, which involves the random exchange
of data between two datasets in order to determine the relationship between them.
For concordance analysis, we focus on the set of common discriminating genes between
two given datasets D1 and D2. Using methods discussed earlier, we can find a set of DGs
from the two classes in D1, and similarly a set of DGs from D2. The genes in both DG
sets were defined as the common DGs. The rationale for our permutation-based approach
is: if two given datasets are similar, then a permutation of samples (for identical tissues)
between them will cause very small change to the set of common DGs. In other words,
the set of common DGs for the two datasets after the permutation should be very similar
to the set for the original two datasets. Thus, by comparing the set of common DGs from
the dataset pair before and after the permutation, we can detect whether the original
dataset pair is concordant or not. We perform a sequence of permutation tests and get a
series of sets of common DGs, and use that series to derive the P-value (Note: While a
large number of common discriminating genes is an indication that the two datasets are
similar, that number alone cannot give us the confidence interval, but the P-value would
be able to do so.)
More specifically, we did the following: (i) we identified the set of common
discriminating genes (CGo) from the original dataset pair; (ii) we did the same for the
dataset pair in the result of random permutations; (iii) we repeated step (ii) m times and
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got m sets (CG1… CGm) of common DGs; (iv) let F = |CGo|, Fi = | CGo ∩ CGi| these
numbers (F1…Fm) had a mean value (mu) and standard deviation (sigma); (v) finally, we
calculated the P-value from ‘F’, ‘mu’ and ‘sigma’ using Chebyshev inequality and tested
whether (F) and (F1…Fm) came from the same population. Let f denote the random
variable of the number of common DGs that occur in CGo. (Observe that F = |CGo

∩CGo|.) We used the Chebyshev inequality to estimate (an upper bound of) the P-value,
which is a frequently used method (Saw J., 1984), as follows:

P (| f − mu | ≥ | F − mu |) ≤

1
(( F − mu ) / sigma ) 2

This estimates the area of the curve in Figure 5.1 where |f-mu| is larger than or equal to
|F-mu| (i.e. situations where f is more extreme than F), which gives us a confidence
interval on a given dataset pair’s concordance.

F
mu

Figure 5.1: Possible distribution of f after many permutations between a dataset pair

5.3.6. Cross platform comparison
The concordance of four different platforms (ABI, AFX, AG1 and GEH) is evaluated.
Essentially the same methods as described above are used, except that, in order to make
the comparison of data from two platforms meaningful, the common genes used in the
two platforms should be determined and the gene expression values should also be
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normalized (see below).
Gene probe matching: Different platforms may use different gene probes. Thus, we
need to find the matching genes between different platforms in order to test their
concordance. To find matching gene probes, we use Unigene IDs. UniGene has been
widely used to match genes on different microarrays, and UniGene IDs are considered to
be the common gene identifier between platforms (Wang et al., 2005). In this study,
utilizing UniGene IDs, 16140 common genes are identified as being present on all four of
the analyzed platforms. Gene expression values are averaged in cases where multiple
probes for a given UniGene ID are present on the chip.
Per-gene baseline adjustment: The gene expression values generated using different
platforms can not be directly compared because of different labeling methods and
different probe sequences used which may give rise to variable signals for the same target
(gene). A per-gene baseline adjustment is performed to normalize these datasets.
Suppose datasets D1 and D2 share m genes (g0 …gm-1) and n tissues (t0…t n-1). Let V1(g k, tj)
denote gene gk’s expression value at tissue tj in D1 and V2(gk, tj) denote the same in D2
where 0 ≤ k < m and 0 ≤ j < n. Define:
MaxDi ,k = Max(Vi ( g k , t j ) | 0 ≤ j < n)
MinDi ,k = Min(Vi ( g k , t j ) | 0 ≤ j < n)
We use the following formula to generate dataset D1’.

V1 ( g k , t j ) =
'

V1 ( g k , t j ) − MinD 1, k
MaxD

2 ,k

− MinD 2 , k

+ MinD 1, k

A similar formula is applied to V2(gk, tj) to generate dataset D2’, where we exchange the
subscript 1 with the subscript 2. The concordance between D1 and D2 can be investigated
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by checking D1’ and D2 (or equivalently D1 and D2’) using classifier transferability,
consistency rate and P-value, as discussed in previous sections.

5.3.7. Absolute distance (AD) and artificial data
For concordance analysis, it is desirable to have a quantitative measure of the amount of
difference between any two given datasets. Here we define one such measure called
absolute distance (AD):
Suppose D and D’ are two datasets which share m genes (g0 …g m-1) and n tissue (t 0…t n-1).
Let V(gi, tj) denote a gene gi’s expression value at tissue tj in dataset D and V’(gi, t j)
denote the same in D’; let Ri denote gi’s expression value range in D, that is, Ri =
max(V(gi, tj) | 0 ≤ j < n) – min((V(gi, tj) | 0 ≤ j < n). The absolute distance from D to D’
(denoted ADD→ D' ) is:
ADD → D ' = ((

∑ (∑ | V ( g , t ) R− V ' ( g , t ) | ) / n) / m) *100%
m −1 n −1
i =0

i

j

i

j =0

j

i

The absolute distance (AD) between D and D’ is defined as:
AD = ( ADD → D ' + ADD ' → D ) / 2
Ri is an important feature for g i in dataset D. For every tissue, V(gi, tj) is in [min((V(gi, tj)
| 0 ≤ j < n), min((V(gi, tj) | 0 ≤ j < n) + R i)]. In D, V(gi, tj) varies less than Ri from tissue to
tissue. If the other dataset D’ is highly concordant with D, then, in every tissue, V’(gi, tj)
should be equal or very close to V(gi, t j). On the other hand, if D’ is not concordant with
D, the difference between V(gi, tj) and V’(gi, tj) may be larger than Ri. Thus, the relative
difference between V(gi, t j) and V’(gi, tj) (normalized by Ri) is a good criterion to define
absolute distance.
Apparently, if for every gene gi, if |V(gi, tj) – V’(gi, tj) | = 0, then AD between D and D’ is
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0, which means that D and D’ are highly concordant; if |V(g i, tj) – V’(gi, tj) | = Ri, then
AD between D and D’ is 100%. In this situation, according to our results, the P-value
between D and D’ is less than 0.01, which means D and D’ are not concordant. Therefore,
this absolute distance measure can be used to indicate how concordant a dataset pair is,
from highly concordant to non-concordant.
In order to evaluate the absolute distance between any dataset pair, we create a series of
artificial datasets with known absolute distance from a given original dataset. These
artificial data may serve as benchmarks to identify how far apart the tested dataset pair is.
The strategy for creating artificial data is as follows: for a given original dataset Dori and
one known absolute distance ADk, we create the artificial dataset Dmodk which differs
from Dori by ADk by modifying every gene’s expression value V(gi, tj) in Dori with value

∆i,j. ∆i,j is randomly chosen and satisfy the following two constraints:
(i). -Ri ≤∆i,j ≤Ri for gene gi,
(ii). ADk = (

∑ (∑ ∆R
m −1 n −1
i =0

j =0

i, j

) / n)m * 100% , where Ri is gene gi’s expression range in Dori.

i

In this study, 10 artificial datasets (D1…D10) are generated from each Dori. The AD
between each Dori and the 10 associated Dmodk are 10%, 20%, ….100%, respectively. A
total of six Dori datasets are used for creating Dmodk. Each of the first four of these Dori
datasets is constructed from the three repeats of one of the four platforms by averaging as
follows: For each platform, let Vm(g i, tj) denote the gene expression value of t j on gi in the
mth repeat of the given platform, and let V(gi, tj) denote the same in the Dori dataset to be
constructed from the three repeats; then V(gi, tj) = (V1(gi, tj)+ V2(gi, t j) + V3(gi, tj))/3. The
fifth Dori is obtained by (1) normalizing (as discussed earlier) and (2) averaging the
expression values of those genes shared by all four platforms of the previous four Dori
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datasets. The sixth Dori is created randomly, where the “expression value” of each gene at
each tissue is randomly generated.

5.4. RESULTS
5.4.1 Concordance test by classifier transferability
We used classifier transferability to evaluate both cross-lab concordance and crossplatform concordance.
For cross-lab concordance, let D and D’ be two datasets respectively generated by two
laboratories using a common platform. We mined discriminating genes from each of the
two datasets, say D, and then used them to build a classifier to predict the class of
samples in the other dataset D’. The classifier’s prediction accuracy is always 100%. This
means that microarray datasets from different laboratories using any of the four given
platforms as a common platform are highly concordant.
Next, the same method was applied to test the cross-platform concordance. Table 5.3
shows the results. The values in the table are the average accuracy achieved by two
classifiers, each of which was built from data generated in one of the two platforms to
predict tissue samples generated in the other of the two platforms. Our results indicate
that the three platforms (AFX, ABI and GEH) are highly concordant with each other, but
the AG1 platform is less concordant with the other three platforms.

Table 5.3: Classifier transferability between platforms
ABI
AFX
AG1

AFX
100%

AG1
62.5%
62.5%
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GEH
100%
100%
60%

5.4.2 Consistency rate (CR) analysis
In order to figure out the influence of noise to microarray dataset’s concordance, and
explain the discordant results in previous papers, the consistency rate (CR) is estimated
before and after the noise genes are removed. As discussed earlier, CR is calculated in
two ways involving two different sets of genes, where one way uses all genes, and the
other uses the discriminating genes only. The results are listed in Tables 5.4 and 5.5.
Table 5.4 shows the consistency rate in intra-platform comparison. If all genes are
included, the consistency rate is around 75% for any two labs within one platform (left);
however, if only the discriminating genes are considered, the consistency rate is between
92% and 98.5% for any dataset pairs (right).

Table 5.4: Consistency rate between laboratories

ABI
AFX
AG1
GEH

L1 vs L2
73.5%
73.5%
79.3%
64.6%

All genes
L1 vs L3
74.6%
74.0%
76.1%
72.6%

L2 vs L3
73.4%
75.7%
77.0%
66.0%

Discriminating genes
L1 vs L2
L1 vs L3
L2 vs L3
98.3%
98.2%
98.5%
97.9%
97.3%
98.1%
98.0%
98.2%
97.0%
92.7%
97.3%
92.5%

L1, L2 and L3 are datasets generated from three different laboratories; each entry in the
table is the consistency rate (CR) between the corresponding laboratory pair

Table 5.5 shows the consistency rate in cross-platform comparison by using either all
genes or discriminating genes only. The discriminating gene-based CR between any
dataset pair is considerably higher than all-gene-based CR except for cases where AG1 is
involved. This result is consistent with classifier transferability result in Section 5.4.1. It
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should be noted that the 50% CR is what would be achieved for a pair of random datasets
after discretization, which has been confirmed by our experiments.

Table 5.5 : Consistency rate across platforms

ABI
AFX
AG1

AFX
73.5%

All genes
AG1
GEH
50.0%
69.1%
50.0%
69.9%
49.6%

Discriminating genes
AFX
AG1
GEH
88.7%
50.4%
83.7%
50.2%
84.1%
50.4%

Each entry in the table is the consistency rate between a platform pair

5.4.3 Permutation and P-value
To quantitatively measure the concordance between two platforms/laboratories, P-value
is calculated directly between the pairs of datasets generated by the two
platform/laboratories. The results are shown in Tables 5.6 and 5.7.

Table 5.6: P-value between intra-platform dataset pair
ABI
AFX
AG1
GEH

L1 vs L2
0.3097
0.5222
0.4099
0.2017

L1 vs L3
0.3068
0.6449
0.3435
0.3475

L2 vs L3
0.3950
0.5109
0.3604
0.2102

According to the calculated P-values, there is no statistical significance (P > 0.05)
between different laboratories using a common platform (see Table 5.6), which implies
that the laboratories are concordant with each other if they use the same platform. The Pvalues for the dataset pairs from different platforms are shown in Table 5.7. There is no
statistical significance between the dataset pairs from platform ABI, AFX and GEH (P >
0.05), which again implies concordance; however, the dataset from AG1 is significantly
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different from the other three platforms (P < 0.05), which implies non-concordance.

Table 5.7: P-value between cross-platform dataset pair
AG1
GEH
AFX
ABI 0.198 0.011 0.201
AFX
0.012 0.286
AG1
0.010

5.4.4 Absolute distance (AD) as bridge
It takes much time to calculate reliable P-value directly by permutation due to two
reasons: (i) In order to get reliable P-value, a fairly large number (at least hundreds) of
permutations are required. (ii) For each resulting dataset pair from these permutations, we
need to compute the discriminating genes by examining up to n3 sets of genes, where n is
the total number of genes. Therefore, to get P-value between a dataset pair directly by
permutation is not very effective. It will be desirable if we can find an alternative way to
obtain P-value such as from known consistency rate. In our approach, we use some
artificial datasets with known degree of absolute distance (AD) to serve as a bridge to
relate P-value and consistency rate (CR). Ideally we want to have a one-to-one
correspondence between AD and CR, and between AD and P-value.

A. Repeatability of artificial datasets
Since the artificial datasets were created randomly (see Section 5.3.7), for a given AD
one may create different datasets at different times. This may cast doubt on whether the
measures and the correlations generated from such artificial datasets are completely
repeatable. Therefore, the repeatability of the correlation between AD and CR/P-value
derived from such artificial datasets needs to be checked.
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Six series of artificial datasets from six original datasets are used to check the
repeatability of the correlation between AD and CR, and between AD and P-value.
Figures 5.2 and Figure 5.3 show the results. Overall, when discriminating genes were
used to calculate CR and P-value, the relationships between AD and CR, and between
AD and P-value were very reproducible and independent of the dataset used, and the
correlations were also quite close to a one-to-one correspondence. This is the case despite
the fact that the six original datasets are very different from each other; in fact, different
datasets (from different platforms) may use sets of genes, the gene expression value
ranges vary considerably between datasets, and one of the six original datasets was
generated randomly.
The CR between each artificial dataset and its original dataset was calculated. (Recall that
each artificial dataset was generated from its original dataset for a given AD) Six series
of artificial datasets produce six CR/AD plots (Figure 5.2). The repeatability of CR/AD
plots is confirmed by the almost exact overlapping of these plots. The maximum CR
difference between the six curves is less than 3% at each absolute distance (X-axis). Thus,
this correlation is considered as very repeatable.
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Consistency Rate
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Figure 5.2: Correlation between absolute distance and consistency rate measure, and
repeatability
Each curve was generated from one of the six series of artificial datasets. The name of the
curve corresponds to the Dori of the series of artificial datasets; CGA in DCGA stands
for Common Gene Averaging, and RAN in DRAN stands for RANdom.

P-values were calculated by permutation test on the six series of artificial datasets
described above. Six series of P-value/AD curves are plotted (Figure 5.3). When the AD
is greater than 60%, the six curves are highly similar to each other. Though there were
minor differences between P-values in these curves when AD is less than 60%, we are
still able to draw consistent conclusion regarding the dataset pair concordance (P>0.05).
Since all P-values were created by random permutation, the more repeats of permutation
we do, the more reliable the P-value will be. In this study P-values were calculated by
100 times of random permutations.
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Figure 5.3 : Correlation between absolute distance and P-value, and repeatability

B. P-value vs consistency rate curve
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Figure 5.4: Consistency rate vs P-value

AD has a near one-to-one correspondence with CR (Figure 5.2), and also good
correlation with P-value (Figure 5.3). Although the correlation between P-value and CR,
established using AD, is not exactly a one-to-one function, AD is still be a valuable way
to tell us how to link consistency rate and P-value, by means of controlled data

71

modification. More specifically, from any given CR we can identify a unique AD
(Figure 5.2), and from each AD value we can identify a small range of P-values. The
correlation between CR and P-value is plotted in Figure 5.4; Table 5.8 lists the
correlation in table form for ease of reference.
This curve can become useful tool for estimating P-value if consistency rate between
dataset pair is known. First, if a CR is given, the range of the corresponding P-value can
be estimated using Figure 5.4 (the range is specified by the pink area). For example,
given a CR of 90% between a dataset pair, the corresponding P-value should be between
0.15-0.25 (and so this dataset pair is concordant). Second, Figure 5.4 shows that if the CR
between a dataset pair is lower than 73%, the P-value between that dataset pair is lower
than 0.05, which implies significant difference, or the dataset pair is not concordant.

Table 5.8 : CR vs P-value
CR
97.9%
88.4%
75.4%
66.3%
59.7%
55.4%
52.9%
51.9%
51.3%

P-value
Lower bound
Higher bound
0.3484
0.4396
0.1476
0.2206
0.0447
0.0515
0.0307
0.0378
0.0200
0.0276
0.0177
0.0267
0.0150
0.0225
0.0129
0.0198
0.0103
0.0184

C. Accuracy testing of P-value vs CR curve
To check the accuracy of the CR/P-value plotted in Figure 5.4, the P-values were
estimated using the CR listed in Tables 5.4 and 5.5. Next, the estimated P-values were
compared with the actual P-value shown in Tables 5.6 and 5.7. As expected, the results
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were consistent with each other. This suggested the plot we got is accurate.
In order to further test the accuracy of the P-value/CR plot, five pairs of datasets are
created randomly. The CR and P-value between each dataset pair are investigated.
Moreover, the P-value is estimated from CR using the P-value/CR plot in Figure 5.4.
Table 5.9 shows the result. One can see that the actual P-value and estimated P-value are
also matched well, which suggests that the plot in Figure 5.4 is accurate.

Table 5.9 : Comparison of P-value from randomly dataset pairs
Dataset pairs
1
2
3
4
5

CR
58.7%
55.5%
92.5%
84.4%
73.7%

P-value from permutation
0.01
0.0093
0.2465
0.1026
0.0483

Derived P-value from CR
0.008 - 0.01
0.008 - 0.01
0.019 – 0.270
0.08 – 0.11
0.046 – 0.049

5.5 DISCUSSION AND CONCLUSION
In this chapter, three comparative analysis methods were introduced to test the
microarray datasets’ concordance. These methods were designed for comparative studies
and focused on discriminating genes in the datasets: classifier transferability tests the
degree of concordance between platforms/laboratories; consistency rate detects
concordance (consistency) between the datasets before and after most of the gene-level
noise is removed (each gene value is discretized to have only 0 and 1); and P-value
quantitatively measures the concordance between platforms/laboratories. In the P-value
based method, numerous and random permutations between datasets were conducted
before the concordance decision is made. Analyzing the datasets provided by MAQC
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project, our results showed that microarray data from different labs within any one of the
four platforms are fairly concordant at discriminating gene level; moreover, crossplatform microarray data derived from ABI, AFX and GEH are also concordant. Our
methods are fairly general, requiring just two tissue types and can be applied to cases
with two or more tissue types or classes.
Our methods have been successfully applied to the datasets with two tissue types. If there
are more than two tissue types in any given datasets, our methods can still be applied. We
have two strategies to handle such datasets. (1) We can randomly divide the tissues into
two classes, and then apply our methods. (2) We can also apply our methods for each pair
of tissue types in the dataset pair, and combine the results for all tissue type pairs together
and find out the concordance between the dataset pair. (If there are n tissue types in the
given dataset, then our methods should be applied n * (n - 1) / 2 times.) Compared with
the first strategy, this strategy is more accurate, although more time consuming.
Noise exists in microarray data. However, having minor differences doesn’t mean that
two datasets must be inconsistent. Some studies (Kuo et al., 2002, Kothapalli et al., 2002)
concluded that the datasets from different platforms are not concordant. They reached
this conclusion by comparing all genes in the microarray data, without filtering out the
noise. In our study, we calculated consistency rate between dataset pairs from different
laboratories and different platforms. If all genes were included, we got conclusion that
the microarray data from different platforms have poor reproducibility. However, when
only considering discriminating genes for analysis, we found that, besides very high
concordant rate within platforms, 3 out of 4 platforms are also concordant with each other
except the AG1 platform.
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Recent publications derived from the MAQC project used some other methods to
conclude that all of the 4 platforms are fairly concordant with each other (Shi et al, 2006,
Guo et al, 2006). Fold-change ranking with a nonstringent P-value cutoff method was
used to rank the genes in these studies. Only the top ranked genes were selected for
platform-concordance analysis for noise removal. After noise removal from the
microarray datasets, it was found that the microarray datasets from different
laboratories/platforms are fairly concordant.
Guo and colleagues also noticed the importance of discriminating genes in concordance
evaluation, although they used the fold change method to discover DGs. It should be
pointed out that the fold change method uses ratio of average of values in the two classes,
whereas the entropy-based method aims to find split values to separate the classes as
cleanly as possible. So their criteria for discriminating gene selection are very different
from ours. We believe that the entropy-based discriminating gene selection method used
in this paper is more biological meaningful. Instead of arbitrarily selecting highly
differentially expressed genes, we selected the genes that participate in discriminating
gene groups; such groups are highly related to one of the classes in the dataset. Thus,
these selected genes may provide insights on gene interaction networks, or even
pathways for the specific disease. Moreover, the entropy based method (Dougherty et al.,
1995) has been widely used in the data mining and machine learning communities (Han et

al, 2006).
It was realized that different gene selection criteria led to different concordance results.
Guo et al used six different gene selection methods to choose and rank genes. They got
different concordance results from their different gene selection methods. In this study,
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we used comparative methods to select discriminating genes for platform concordance
testing. Compared with their results, we reached the same conclusion that the datasets
within a given platform are highly concordant, and that the non-AG1 platforms are fairly
concordant with each other. However, we assessed that the AG1 platform has low
concordance with other platforms according to the datasets provided by MAQC project,
whereas Guo et al concluded that the AG1 platform is also concordant with other
platforms. While the agreement results reinforce previous results and indicate that most
platforms are concordant with each other, the disagreement was the results of using
different gene selecting and testing methods.
Our conclusion can be helpful for the future comparative studies. For example, since
AG1 and other platforms are not concordant under comparative discriminating gene
selection, the datasets from AG1 can’t be analyzed together with the datasets from other
platforms in comparative studies, such as discriminating gene data mining. On the
contrary, these datasets can be analyzed together under fold-change ranking with a
nonstringent P-value cutoff method.
It should be noted that, the concordance results reported in this paper were based on
datasets from MAQC, which were derived from well controlled experiments and identical
reference RNAs. In real world situations one also needs to consider lab-practice
variability and biological variability, which will be discussed in Chapter 6.

5.6 APPENDIX
Since discriminating genes play a key role in microarray dataset, it is tempting to use the
percentage of number of common discriminating genes (which we refer to this approach
as the basic discriminating gene transferability) to directly measure the concordance
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between a dataset pair, or to use the binning cut-point difference of common
discriminating genes to test the concordance. If one or both of these two methods can
serve as such a measure, the concordance between a dataset pair can be easily determined.
Unfortunately, none of these methods work for microarray gene expression data, because
for concordance determination, both methods are sufficient condition, but not necessary
condition. In other words, two datasets with a small number of common discriminating
genes or with a large cut-point difference may still be highly concordant.
We created four datasets pairs with controlled degree of concordance to test the above
two methods. Dk and Dk’ is one dataset pair, where 0<k≤4; Nk is the number of
discriminating genes in dataset Dk; Nk’ is the number of discriminating genes in dataset
Dk’; Ck is the number of common discriminating gene in both Dk and Dk’. The CDG
Ratio (common discriminating gene ratio which is mined using basic discriminating gene
transferability) between one dataset pair is calculated by the following formula:
CDG ratiok = (Ck * 2) / (Nk + Nk’) * 100%.
The CP Diff (cut point difference) is calculated as the following:

CP Diff k = (

∑ (| V (c ) − V (c ) | / R )) / n *100%
n −1

'

k

i

k

i

ki

i =0

where Vk(Ci) and Vk’(Ci) denote gene gi’s cut point at dataset pair k, and Ri is gi’s
expression value range. The testing results are shown in Table 5.10.
Table 5.10: Comparison of dataset concordance using different methods

Dataset
pairs
1
2
3
4

CP
diff
17.0%
17.8%
17.3%
18.2%

CDG Ratio
81.6%
71.3%
72.2%
52.8%

Classifier
transferability
100%
82.5%
74.0%
50.5%
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Consistency
rate
99.5%
89.4%
78.6%
52.5%

P-value
0.6563
0.1326
0.0527
0.0082

Four pairs of datasets were created in a controlled manner: dataset pair 1 is highly
concordant between each other; dataset pair 2 is concordant; dataset pair 3 is on the
boundary of concordance and dataset pair 4 is not concordant.

In Table 5.10, besides cut-point difference and CDG Ratio, the classifier transferability,
CR and P-value result are also listed for comparison. According to the table, classifier
transferability, CR and P-value can act as very good criteria to scale the concordance
between dataset pair, but cut point difference and CDG ratio can’t.
The following are weakness of these two methods. Suppose there are m tissues in dataset
D. So each gene gi has m expression values in D. (1) the basic discriminating gene
transferability uses the number of common discriminating genes as criterion. For any
discriminating gene gi, if its expression value at one tissue is slightly modified so that it
crosses the old binning cut point, then this gene might not be a discriminating gene
anymore. Thus, one expression modification in one tissue may affect the whole gene’s
property, which makes this method very vulnerable. (2) gi’s cut point is highly dictated
by the two expression values which are closet to the cut point and which envelope the cut
point So the cut point difference between dataset pair is mostly dictated by those two
expression values of gi and is insensitive to the others. Thus, it can’t represent the
behavior of gi, and it can’t serve as an indicator for concordance test either.
Our analysis of the data on these two methods also indicated the following interesting
observations: (1) most consistent genes between a dataset pair are discriminating genes.
(2) Consistency rate for non-discriminating genes is positively correlated to the
consistency rate for discriminating genes, although the consistency rate for the former is
much lower than the latter.
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Chapter 6: MINIMIZING VARIABILITY OF
MICROARRAY DATASETS
6.1. MOTIVATION
During comparative microarray data mining, it is very important to get reliable patterns
and models in order to gain high-quality understanding the mechanism of specific
diseases. It has been well known that there is variability in microarray datasets and the
variability may affect the data mining results. So far, few reports, if any, used
comparative methods to study this topic. In this chapter, we investigate the effect of
variability, develop novel methods to reduce the variability, and improve the reliability of
the mined patterns and models.

6.2. OVERVIEW
Ideally, if there were no variability in microarray datasets, the mined patterns and models
should represent the intrinsic features of the classes they belong to. They should be
independent of the chosen patient samples, laboratories and platforms which were used to
generate the microarray datasets. Roughly speaking:
•

Data mining results from multiple microarray datasets concerning a common
disease should be identical or highly similar;
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•

Data mining results from different subsets of one microarray dataset should be
identical or highly similar.

Unfortunately, variability exists in microarray datasets. Such variability includes
measurement variability, biological variation and so on (Chapter 2, Section 2.2).
Microarray datasets are generated from different laboratories using different platforms.
Experimental noise exists during the data generation of microarray experiments, which
might cause inconsistent results and produce measurement variability. We have tested
this effect of experimental noise in Chapter 5. Our results showed that, at comparative
level, the datasets from a common platform, different labs are highly concordant.
At the same time, microarray datasets are typically generated using tissue samples from
different patients. These patients have different characteristics such as height, weight, age,
race, sex etc. These differences inevitably lead to biological variations in the microarray
datasets and may affect data mining results and conclusions. Compared with
measurement variability, which randomly distributes through the datasets, biological
variation is sample specific. Some samples may bring high degree of biological variation
to the dataset and thus influence the data mining results.
In this chapter, we consider how to test and minimize the variability by identifying and
eliminating noisy tissue samples from datasets. The noisy samples may have high degree
of biological variation, or they may have high degree of measurement variability.
More specifically, first we use four measurements to evaluate the degree of variability.
Then we develop a novel method which is called Converged Leave-One-Out-Cross
Validation (C-loocv) to identify and remove the samples which have high degree of the
variability in microarray datasets. This process is called biological variability
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minimization (BVM). Next we compare the data mining results from the original datasets
with those from the C-loocv refined datasets. And finally we show the advantage of Cloocv application in classification.

6.3. MATERIALS AND METHODS
6.3.1. Microarray datasets for variability evaluation
In this chapter, two microarray datasets which study lung cancer will be used to evaluate
the effect of variability on our data mining results. These two datasets were generated in
different laboratories. One dataset was created by Bhattachariee and colleagues
(Bhattacharjee et al, 2001) in Harvard medical school, which is called Harvard lung
cancer dataset or Harvard in this study. The other one was created by Beer and colleagues
(Beer et al, 2002) in University of Michigan, which is named Michigan lung cancer
dataset, or Michigan in this study. Both datasets study lung cancer using samples from
different patients. These two datasets made it possible to check the influence of
variability on the data mining results.
There are totally 12,600 DNA probes (genes) and 203 samples in Harvard microarray
dataset. 17 samples come from normal lung (Normal), and the other 186 samples are
from lung cancer patients (Tumor). These tumor samples are further divided into five
subtypes: (1) lung adenocarcinomas (n = 127); (2) squamous cell lung carcinomas (n =
21); (3) pulmonary carcinoids (n = 20); (4) small-cell lung carcinomas (n = 6) and (5)
Other adenocarcinomas (n = 12). In our study, all tissue samples in five tumor subtypes
are considered as lung cancer samples and categorized in one group. Thus, there are two
classes in this dataset: Normal class (n = 17) and Tumor class (n = 186).
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Compared with Harvard dataset, Michigan dataset is relatively smaller in size and
simpler in structure. There are 7129 gene probes and 96 samples in Michigan dataset.
Among 96 samples, 10 of them come from normal controls; the other 86 samples are
from lung cancer patients. These cancer samples are separated into two subgroups: 67 are
stage I and 19 are stage III lung cancer. Same as Harvard dataset, in our study, the cancer
samples from two subgroups are categorized into one class. So there are also two classes
in Michigan dataset: Normal class (n = 10) and Tumor class (n = 86).
Even though both lung cancer datasets were created using a common platform
(Affymetrix), the total number and the order of gene probes on the two chips are different.
Thus, the common genes between these two datasets should be identified. Same as
Chapter 5, we will use UniGene IDs to identify the common genes between these two
datasets. Gene expression values are averaged in cases where multiple probes for a given
UniGene ID are present on the chip.
Because variability in microarray datasets includes measurement variability and
biological variation, it is desirable to test the effect of measurement variability and
biological variation separately. MAQC datasets make it possible. The details about
MAQC data structure have been introduced in Chapter 5. Since all MAQC datasets use
same mRNA as tissue samples, biological variation is supposed to have been eliminated.
Thus, MAQC datasets should be very appropriate to test the effect of variability caused
only by measurement variability.

6.3.2. Measurements of the degree of variability
It is difficult to measure the degree of variability in microarray datasets directly. So far,
no study has been reported to define the degree of variability in microarray datasets; as a
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result, no attempt has been made to measure it. Here, we define the degree of variability
between datasets (see note below) as the similarity of data mining results mined from
such microarray datasets. High degree of variability produces low similarity of data
mining results, and vice versa.
In this chapter, we measure the similarity of data mining results mined from microarray
datasets to evaluate the degree of variability. Roughly speaking, agreements on each of
the following four types of data mining results obtained from datasets will be used to
evaluate the degree of variability, (1) the sets of top 20 ranked genes from each dataset;
(2) classifier transferability (CT) between datasets; (3) the sets of discriminating genes
(DGs); and (4) the sets of top frequency HDGGs.
More specifically, first, we rank the genes in each dataset in decreasing information gain
order and obtain the top 20 gene sets from each dataset. Meanwhile, we discover highly
differentiative gene groups (HDGGs) from each dataset by using “iterative gene club
formation algorithm” (Mao & Dong, 2005) and border differential algorithm (Dong et al,
1999). Recall that genes involved in HDGGs are discriminating genes.
Next, the similarity of the top gene sets between datasets is evaluated using Jaccard
similarity coefficient (JSC). Identical criteria are also used to measure the similarity of
DG sets and HDGGs sets. The Jaccard similarity coefficient (JSC) is calculated to check
the similarity of two sets, which is defined as the size of the intersection divided by the
size of union of the sample sets. Thus, the range of JSC is [0, 1].
Finally, the discriminating genes from each dataset are used as classifier to test classifier
transferability between datasets. (Details about classifier transferability have been
described in Chapter 5). The range of classifier transferability (CT) is [50%, 100%].
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Note: the term “datasets” used in this chapter means the datasets which study a common
disease. Such datasets are suitable for analyzing the degree of variability. If only one
microarray dataset is under consideration, we make several subsets by randomly choosing
samples from each class in this dataset. These subsets are used as “datasets” for
variability analysis.

6.3.3. Converged Leave-One-Out Cross-Validation algorithm (C-loocv)
In microarray datasets, the tissue samples come from a variety of patients. Some samples
may be highly different from the others in the same class. These noisy samples cause
high degree of variability and should be eliminated from microarray datasets. Liu and
colleagues (Liu et al, 2001) developed a so-called ICF algorithm to eliminate noisy
samples from datasets. In this study, we develop a new algorithm (C-loocv) by improving
Liu’s algorithm and apply it on microarray datasets. C-loocv is created by combining
leave-one-out cross validation algorithm with our HDGG-based classifiers. In our
microarray datasets, C-loocv will be applied to identify and eliminate noisy samples.

A. Leave-One-Out-Cross-Validation (LOOCV)

Leave-one-out cross-validation (LOOCV) has received much attention since it has been
shown to give an almost unbiased estimator of the generalization properties of statistical
models, and therefore provides a sensible criterion for model selection and comparison.
The original purpose of LOOCV is to compare the robustness of classifiers. In a given
dataset, one test sample (an unobserved output value ‘y’) is left out and the other samples
(an observed vector ‘x’) are used to train the classifiers. The trained classifiers are
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applied to predict ‘y’. The classifiers with better predicting accuracy are considered as
more robust. Whenever a new classifier is developed, LOOCV is a common method to
test this classifier’s robustness by comparing with other classifiers.
During classifier’s robustness comparison, it has been noticed that in some datasets,
several specific samples could not be predicted correctly no matter which classifiers were
applied. This fact led us to consider the reliability of the dataset itself other than that of
the classifiers.
As mentioned before, many factors, such as biological variation, high risk normal
controls, misdiagnosis patients and so on, may cause the test samples to be categorized
into the incorrect class during microarray dataset generation. According to this fact, we
will develop algorithms to identify and remove those wrong-predicted samples from
datasets in order to improve reliability.

B. Building high accuracy HDGG-based classifiers

HDGG-based classifiers have shown improvement in predicting accuracy over the other
classifiers. The algorithm for building HDGG-based classifier was mentioned in Chapter
4. Here, we discuss in detail how to build this classifier.
Suppose a cancer related microarray dataset D has n tissue samples (t0…tn-1). These
samples can be divided into two classes according to its class type: “Normal” class CN
which has n1 samples, and “Tumor” class CT which has n2 samples; the HDGGs are
mined from CN and CT and will be used to build a HDGG-based classifier. Let’s denote
the ranked tumor HDGGs in CT as HDGGT1, HDGGT2 … HDGGTx in descending order
of their frequency in CT. Similarly, denote the ranked normal HDGGs in CN as HDGGN 1,
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HDGGN2 … HDGGNy also in descending order of their frequency. Next, some normal
HDGGs and tumor HDGGs are chosen to build a classifier with gene diversity strategy as
mentioned in Chapter 4, i.e. each discriminating gene occurs no more than once in the
chosen HDGGs. For example, if one discriminating gene ‘g’ appears in HDGGT1, then all
other HDGGTs which contain ‘g’ are not allowed to serve in the classifier.

Suppose the following are the HDGGs selected for use in the classifier, using the gene
diversity strategy:
Tumor class (CT): HDGGTx1, HDGGTx2…HDGGTxi, where x1<x2<xi≤x
Normal class (CN): HDGGNy1, HDGGNy2…HDGGNyj, where y1<y2<yj≤y

In order to predict the class type of a test sample T, the score of the class label of T needs
to be calculated. Suppose we use k (k < i and k < j) top-ranked HDGGs from CT and CN
in the scoring process. Then we define the score of T in the CT class as

S (T ) _ CT = (

∑
z =1

frequency( HDGGT xz )
)/k
n2

∑

frequency( HDGG N yz )
)/k
n1

k

and the score of T in the CN class as
S (T ) _ C N = (

k

z =1

Finally, the test sample T’s score is: score(T) = S(T)_C T – S(T)_CN.
According to the formula, one can see that for any sample T, -1 ≤ score(T) ≤ 1. If score(T)
> 0, then sample T is predicted as tumor; if score(T) < 0, then T is predicted as normal;
score(T) = 0 means we have a tie and T’s class is difficult to decide. If score(T) is close
to 1 or -1, T typically belongs to the corresponding class (Tumor or Normal).
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The parameter k can be determined by the user based on the available computation power.
In this research, in order to obtain the maximum information from the training datasets
and make the classifiers as diversity as possible, we keep the number of HDGGs in
classifiers as large as possible. Thus, in this study, k = i (if i < j), or k = j (if j < i); in
other words, k is the minimum of the numbers of top-ranked HDGGs for the two classes.

C. The Converged loocv (C-loocv) Algorithm:
The C-loocv algorithm is designed to identify noisy samples by comparing each testing
sample’s score using HDGG-based classifiers. This design requires that the scores from
every sample (T) be comparable. We modify the definition of score(T) in order to fit the
C-Loocv algorithm:
For any sample ti, if ti’s original class is “Tumor”, the score of ti is defined as:
score(ti) = S(ti)_CT – S(ti)_CN
Otherwise, if t’s original class type is “Normal”, then:
score(ti) = S(ti)_CN - S(ti)_CT
This modification ensures that tumor samples and normal samples can be compared
together.
The following is C-loocv algorithm.
Suppose the given cancer related microarray dataset D has n tissue samples (t0…t n-1).
Step 1: Every sample ti in D is separated as test sample (so the rest are used as training
samples); this yields a score(ti);
Step 2: Rank the samples in descending order of their scores;
Step 3: Remove the samples whose scores are less than threshold τ;
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Step 4: In the remaining samples, repeat steps 1 to 3 until every sample’s score is larger
than τ. Now the “core dataset” is obtained;
Step 5: Use the core dataset as training data to build classifiers and to predict the
discarded samples in step 3 and rank them in descending order;
Step 6: Restore the samples whose scores are larger than τ, and permanently discard the
samples whose scores are less than τ. Suppose the number of discarded samples is n 1,
then the number of remaining samples in D is n – n 1;
Step 7: Repeat steps 1 to 6 on D until the dataset reaches steady state, i.e. no more
samples are added or removed; we have now reached the converged state.
In this study, the threshold τ is set to 0. We can adjust the threshold in order to find the
best optimization for any given datasets. According to score(T)’s formula, if τ is set
larger than 0, then some test samples which weakly belong to their class are also
discarded; if τ is set less than 0, the test samples which are slightly predicted wrong are
kept in the dataset.

6.4. RESULTS OF EVALUATING OUR METHOD
As mentioned before, four measurements are used here to test the degree of variability in
datasets. We focus on two measurements: one is the sets of top 20 genes, the other one is
classifier transferability (CT). The other two measurements (sets of discriminating genes
(DGs) and sets of HDGGs) are used as reference.
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6.4.1. Degree of measurement variability
Since variability includes measurement variability and biological variation, it is desirable
to test measurement variability alone. According to MAQC style dataset structure, there
is no biological variation in MQAC datasets. Thus, we can test the degree of variability
caused only by measurement variability using these datasets.
Two datasets (ABI_L1 and ABI_L2) from ABI platform are chosen. Using entropy-based
gene ranking method, several thousands of genes have equally information gain and can
be ranked as top genes simultaneously. We further re-rank these top ranked genes
according to their gene index number in their respective datasets (small index number
ranks higher). Table 6.1 shows the top 20 genes from each dataset.
Table 6.1: Top 20 genes in two datasets generated with ABI platform
Rank order
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

ABI_L1
1
4
5
6
7
10
15
16
17
18
24
26
27
31
33
34
37
44
47
55
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ABI_L2
1
4
5
6
7
10
13
16
17
18
24
26
27
31
33
34
37
39
42
44

According to Table 6.1, we notice that the sets of top 20 genes from two datasets are
quite similar. 85% of genes in the top 20 gene sets are identical (bold font). The Jaccard
similarity coefficient (JSC) between these two sets is 0.739.
Classifier transferability (CT) between these two datasets is also calculated: CT = 100%.
We also calculate the JSC value from the sets of DGs and the sets of HDGGs. JSC =
0.676.
According to these results, we conclude that measurement variability exists in the
datasets and moderately affect the top 20 gene ranking. But it has no effect on classifier
transferability. This is consistent with the results in Chapter 5.

6.4.2. Artificial dataset with maximal degree of variability
In Section 6.4.1, we tested our measurements using MAQC datasets which have minimal
degree of variability (no biological variation). We also need to test our measurements
with the datasets which have maximal degree of variability. Clearly, for any two datasets,
if JSC = 0 and CT = 50%, then the degree of variability in those datasets is maximal.
In order to obtain such datasets, we randomly swap several samples between two classes
in one dataset. In ABI_L1 dataset, we exchange several samples in t1 … t10 with the
corresponding samples in t11 … t20 (see Table 5.1). After sample swap, the modified
dataset is named as ABI_L1’. Top 20 genes are ranked from two datasets (ABI_L1 and
ABI_L1’). As expected, there is no common gene shared by the two sets of top 20 genes
(JSC = 0 and CT = 50%). In fact, after we exchange only four samples (t1 vs t11and t2 vs
t12), we have gotten maximal degree of variability. The top 20 genes in both sets have
already become completely different (Table 6.2).
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Table 6.2: Top 20 genes before vs after sample swap
Rank order
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

ABI_L1
1
4
5
6
7
10
15
16
17
18
24
26
27
31
33
34
37
44
47
55

ABI_L1’
11535
441
500
580
666
694
792
1086
1334
1381
1550
1565
1669
1711
1802
1828
1942
2277
2809
2882

In Table 6.2, the second column is the top 20 genes from original ABI_L1 dataset. The
third column is the top 20 genes from dataset ABI_L1’, in which two pair of samples are
swapped.
We use our C-loocv algorithm to identify noisy samples from ABI_L1’. These swapped
samples can easily be identified and eliminated. After noisy sample removal, the data
mining results from the refined datasets become highly consistent.

6.4.3. Variability in lung cancer datasets
As mentioned before, both Harvard and Michigan datasets study lung cancer and both of
them were generated using the Affymetrix platform. We have proved that datasets
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without biological variation, which come from a common platform and different
laboratories, are highly concordant (see Chapter 5). Thus, if no biological variation exists
in the two lung cancer datasets, the top 20 gene sets from both datasets should be
identical or very similar, and classifier transferability (CT) between these two datasets
should be 100% (see Section 6.4.1).
Top 20 gene sets: Table 6.3 shows the sets of top 20 genes mined from Harvard and
Michigan datasets. The number in the table is the gene’s index number, i.e, each number
represents one specific gene.
Table 6.3: Top 20 genes in Harvard and Michigan lung cancer dataset
Rank order
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Michigan
845
1344
1814
2040
2910
3895
711
2275
2607
2688
3581
3945
4020
4145
3136
223
997
2287
2508
2736

Harvard
2910
640
2688
2607
4351
5180
3284
845
1344
2555
1981
3895
3911
4598
2956
123
1814
3945
4657
4165

The top 20 genes from the two datasets are not very similar. Only 40% of the genes are
shared in both gene sets. We use bold-number to mark the common genes in both top 20
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genes from two datasets. The JSCtop20 is equal to 0.25. The rankings of some specific
genes differ greatly between two datasets. For example, gene 2040 ranks top 4 in
Michigan, but ranks very low (top 91) in Harvard. We also mined the HDGGs and
discriminating genes (DGs) from both datasets. The JSCDG is equal to 0.184, and
JSCHDGG is equal to 0.056 between Michigan and Harvard datasets. The details about the
sets of DGs and the sets of HDGGs are listed in Section 6.6, Table 6.6 and Table 6.7.

Classifier transferability: CT between two datasets is not very high. When Harvard
dataset is used to build HDGG-based classifier to test the tissue samples in Michigan
dataset, the predicting accuracy is 55.2%. When Michigan dataset is used to build
HDGG-based classifier and predict Harvard dataset, the accuracy is 83.6%. Therefore,
the classifier transferability (CT) between Harvard and Michigan datasets is CT = (55.2%
+ 83.6%) / 2 = 69.4%.
These inconsistent data mining results indicate that there is high degree of variability in
Michigan and/or Harvard datasets. Therefore, we will minimize the variability in next
section.

6.4.4. Biological variability minimization (BVM)
Both Michigan and Harvard datasets are treated with C-loocv in order to find and remove
the noisy samples. It takes less than 10 cycles before the datasets reach steady state. After
C-loocv processing, the new datasets are named as refined (Michigan/Harvard) datasets.
In contrast, before C-loocv, the datasets are called original datasets.
Several samples are removed by C-loocv. In Michigan, 5 samples are eliminated. These
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samples include 3 tumor samples (stage I lung cancer, patient number 16, 19 and 54) and
2 normal samples (patient number 88 and 90). In Harvard, 13 samples are eliminated.
They are 10 tumor samples (patient 15, 17, 21, 76, 83, 117, 121, 132, 135 and 137) and 3
normal samples (patient number 193, 199 and 203). After BVM, there are 91 samples in
refined Michigan dataset and 190 samples in refined Harvard dataset.

JSC from refined datasets: Top 20 genes are mined from both refined datasets. The
results show in Table 6.4.
Table 6.4: Top 20 genes in refined Harvard and Michigan lung cancer datasets
Rank order
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Michigan
711
845
1344
1814
2040
2275
2287
2607
2910
3136
3581
3895
4020
5269
123
1981
2555
2688
3945
2956

Harvard
640
845
1344
2607
2688
2910
4351
2555
3895
2956
3197
3284
123
1814
1981
1241
3911
4704
2916
3945

The similarity of data mining results from the two refined datasets is improved. 60% of
the genes appears in both top 20 genes sets (bold font) and JSC(top20, BVM) = 0.43. Recall
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that before BVM, JSCtop20 = 0.25. We also compare sets of top 40, top 60 and top 80
genes from both datasets before and after BVM. All of them show that after BVM, the
Jaccard similarity coefficient value increases. We test the discriminating gene sets and
HDGG sets too. After BVM, the number of common genes in both discriminating gene
sets and HDGG sets also increased. JSC(DG,

BVM)

= 0.40 and JSC(JEP,

BVM)

= 0.357 in

contrast with JSCDG = 0.184 and JSCJEP = 0.056. Detailed gene lists can be found in
Table 6.6 and Table 6.7 in Section 6.6.

Classifier transferability (CT) between refined datasets: The CT between refined
datasets improved. Using HDGG-based classifier built from Harvard tests Michigan, the
accuracy is 83.7%; meanwhile, using classifier built from Michigan test Harvard, the
accuracy is 93.8%. Thus, the CT reaches (83.7% + 93.8%)/2 = 88.8%. Recall that before
BVM, the transferability is only 69.4%. CT significantly improved due to our BVM.
The above results indicate that using C-loocv, we can effectively minimize the biological
variability and improve the reliability of datasets.

6.5. CLASSIFICATION IMPROVEMENT
BVM with C-loocv has many advantages and significances in data mining. Besides
minimizing the degree of variability in microarray datasets, BVM also increases the
predicting accuracy during classification process. This was mentioned in Section 6.4.4:
classifier transferability improved significantly when using classifiers built from refined
datasets. Therefore, C-loocv can be a very good algorithm to improve the robustness of
trained classifiers.
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Many classifiers such as SVM, PCL, HDGG-based classifiers and so on, can predict
unknown samples with very high accuracy. But in some datasets, some specific samples
can not be predicted correctly no matter which classification methods/classifiers were
applied.
High degree of variability in these datasets is one of the major reasons. In addition, the
difference of gene expression range between training and testing datasets is another factor.
By using C-loocv to identify and remove noisy samples from training datasets, the
situation can be significantly improved. Further, when the baseline is adjusted between
training and testing datasets, we obtain even better results. Next, we will show that our Cloocv algorithm gives very good results on several public microarray datasets.

A. Prostate cancer microarray dataset:
Prostate cancer is another very common cancer worldwide. One microarray dataset
focusing on prostate cancer was generated several years ago (Singh et al, 2002). This
dataset was created using Affymetrix platform. It includes 12,600 gene probes and 136
tissue samples. The samples were further divided into two subsets: 102 samples were
used as training dataset and 34 samples as testing dataset. Both datasets contain tumor
samples and normal samples. This is a very well designed dataset for testing the
robustness of classification methods, i.e. building different classifiers from training
dataset and using each of them to predict the samples in testing dataset. The robustness of
each classifier can be evaluated by their predicting accuracy.
Until now, no classification methods can predict the samples in Singh’s testing dataset
with high accuracy. The highest predicting accuracy is around 50% so far (Tan et al
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2003b). We also tested our HDGG-based classifier on this dataset. The predicting
accuracy is nearly 50%. Many reasons may be responsible for the poor predicting
accuracy. Among them, biological variability is one of the major factors.
In order to minimize biological variability, we use C-loocv algorithm to refine the
training dataset and eliminate noisy samples. After BVM, totally 20 samples are
eliminated. These discarded samples include 15 tumor samples and 5 normal samples.
When a classifier is built from the refined training dataset and applied to test the original
testing dataset, the predicting accuracy increases to 73.5%. Though this accuracy rate is
not very high, it improved greatly compared with the highest previous accuracy rate.
As discussed in Section 5.3.6, each individual gene’s expression value in two datasets
should be normalized to identical or similar range before these two datasets can be
studied together. In Singh’s dataset, nearly one-third of the gene’s expression values in
training and testing dataset were not in the same range. For example, gene 8’s expression
range is [-11, 94] across 102 samples in training dataset, but it is [414, 2017] across 34
samples in testing dataset.
Per gene range based normalization (Chapter 5) was applied to normalize training and
testing dataset, the predicting accuracy reaches 85.3%. If C-loocv algorithm is applied on
the top of gene range based normalization, the predicting accuracy increases to 94.1%
(only 2 of 34 testing sample were wrongly predicted). (Table 6.5)

B. Breast cancer microarray dataset:
Breast cancer is the most prevalent cancer in women in the US. One microarray dataset to
study breast cancer was created by van’t Veer and colleagues (van’t Veer et al 2002 ). This
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dataset is also divided into training dataset (78 samples) and testing dataset (19 samples).
The predicting accuracy was low using current classification methods. When using
HDGG-based classifier built from training dataset, 6 samples were wrongly predicted.
After gene range based normalization between training and testing datasets, 5 samples
were still incorrectly predicted.
Then, C-loocv algorithm is used to refine the training dataset and eliminate noisy samples.
Totally 31 samples were eliminated from training dataset. When HDGG-based classifiers
are built from the refined training dataset on top of gene range based normalization, the
predicting result improved significantly. Only 2 samples in original testing dataset were
mis-predicted (Table 6.5).

C. Leukemia dataset:
In some public cancer related microarray datasets, such as Leukemia dataset (Golub
1999), the testing samples have been predicted with very high accuracy using current
classifiers. However, we can get higher predicting accuracy by using baseline adjustment
and C-loocv algorithm.
Leukemia dataset includes both training dataset (38 samples) and testing dataset (34
samples). With our HDGG-based classifier built from the original training dataset, 4
samples were predicted incorrectly. After baseline adjustment between the training and
testing dataset and C-loocv, our HDGG-based classifier built from the refined training
dataset achieved a predicting accuracy of 94.1% (only 2 wrongly predicted samples).
(Table 6.5)
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Table 6.5: predicting accuracy improvement with C-loocv and baseline adjustment
Datasets

Original

Prostate cancer
Breast cancer
Leukemia

50%
68.4%
88.2%

Baseline
adjustment
85.3%
73.7%
91.2%

C-loocv
73.5%
68.4%
91.2%

C-loocv with
Baseline adjustment
94.1%
89.5%
94.1%

Table 6.5 shows the improvement of prediction accuracy using baseline adjustment
or/and C-loocv. The values in the table are the predicting accuracy rate in percentage.
HDGG-based classifier was used for predicting testing samples. The second column
shows the results with the classifier trained from the original training dataset. The
training dataset was treated with baseline adjustment (3rd column) or C-loocv (4th column)
respectively before the classifier was built. The fifth column demonstrates the results
where both treatments were performed.

6.6. CONCLUSION AND DISCUSSION
High degree of variability in microarray datasets affects data mining results, makes them
unreliable, and affects the robustness of classifiers. Because of the existence of noisy
samples, the training process may be misled and the established classifiers may not fully
embody the intrinsic difference between the two classes within one dataset. In other
words, they are not as robust as they should be since the most significant differences
between two classes may have been quenched by the noisy samples. Thus, it is hard to
get high predicting accuracy using such classifiers.
In microarray data mining, we are the first one to evaluate the effect of variability on data
mining results using comparative methods and to provide methods to minimize
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variability. Our attempt turned out to be promising and useful.
We developed the C-loocv algorithm to minimize variability in microarray datasets by
improving Liu’s algorithm. Compared with Liu’s algorithm, our method is more general.
HDGG-based classifiers have been proven to be very robust (Chapter 4). LOOCV
examines the instances one by one and treats every instance equally. Every instance in a
given training dataset participates to decide the testing instance’s class type. This is better
than the k-NN method, in which only k instances are used to predict the testing instance.
The choice of value ‘k’ is important because different k value may cause different
predicting result, and it is a difficult issue.
The C-loocv algorithm effectively eliminates noisy samples and reduces variability. After
datasets are refined by C-loovc, the predicting accuracy increases significantly, and the
consistency of data mining results is also improved.
However, though the consistency of data mining results is improved by BVM, it did not
reach our expected level. For example, there is still big divergence of data mining results
between Harvard and Michigan datasets as shown in Table 6.3, Table 6.6 and Table 6.7.
We also tested another dataset (Singh et al, 2002) and obtained similar results. We mined
top 20 genes from original training and testing datasets in this prostate dataset, and only 2
genes were shared in the two top 20 gene sets. After BVM with C-loocv, we got 6
common genes in both sets (recall that the predicting accuracy has been dramatically
improved after C-loocv). This large gene difference (14 genes were difference between
two sets) indicated that the training dataset and testing dataset are not very consistent
with each other, even though biological variability has been minimized.
The fact that the ultimate results did not reach 100% consistency might have been caused
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by many reasons. One of them is the tradeoff of biological variability versus bias. Most
microarray datasets have large number of genes and relatively small number of samples.
These samples may not fully reflect the intrinsic class features, and they may lead to data
mining results which are not fully consistent.
During biological variability minimization, if a small value of threshold τ is chosen,
fewer samples are eliminated and the data mining results may not improve significantly.
On the other hand, if larger value of τ is chosen, more samples are removed and few
samples remain, the bias may rise and mislead the results.
Based on our results in this chapter, we realize that the variability and some other reasons
make big impact on the HDGGs we mined. In order to get more reliable HDGGs from
current highly variable microarray datasets, we are going to mine so called “invariant
patterns” from several microarray datasets which focus on a common disease. The
methods and results will be shown in Chapter 7.

6.7. APPENDIX
In this section we will show the sets of discriminating genes and the sets of HDGGs
mined from Michigan and Harvard lung cancer datasets.

6.7.1 The sets of discriminating genes (DGs)
Discriminating genes have been proved to be of great importance, because they contain
valuable information in each specific dataset. The similarity between the sets of
discriminating genes from two datasets is another good criterion to test biological
variability. If there is high degree of biological variability in datasets, the discriminating
genes and the number of discriminating genes from these datasets will become quite
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different. Table 6.6 shows the DG sets from two lung cancer datasets before and after
biological variability minimization (BVM).
Table 6.6: Discriminating genes in Harvard and Michigan lung cancer datasets
Original datasets
Michigan
Harvard
223
640
483
845
1210
640
1344
845
2302
997
2555
1086
2607
1344
1526
2688
1690
2910
1814
2956
3104
2040
3207
2275
3550
2287
4351
2508
4657
2607
2688
2736
2910
2956
3136
3581
3784
3895
3945
4020
4145
4180
4366
4598

Refined datasets
Michigan
Harvard
123
123
640
640
796
845
1344
845
1814
961
1981
1035
1100
2040
2275
1344
1600
2287
1797
2555
1814
2607
1981
2688
2910
2040
3136
2287
3581
2555
3895
2607
3945
2688
4020
2910
4145
2941
2956
4165
3012
3038
3284
3581
3895
4020
4165
4351
4657

The contents in Table 6.6 are the discriminating gene index numbers. We use the bold
font to show discriminating genes shared by both Harvard and Michigan datasets. Before
BVM, there are 16 and 29 discriminating genes in Michigan and Harvard datasets
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respectively. Among them only 7 common DGs are in both sets (JSCDG = 18.4%). After
refining the datasets by BVM, the numbers of discriminating genes in two datasets
become 20 and 29 respectively, and 14 of them are shared by two datasets (JSC(DG, BVM) =
40%). The improvement of common DGs indicates that C-loocv algorithm can
effectively reduce biological variability.

6.7.2. The sets of HDGGs (JEPs)
HDGGs have been proved to be very useful for discovering the inherent distinctions
between different classes within one dataset (Chapter 4). It is also one important
characteristic of a given dataset. The similarity of the sets of HDGGs from two datasets is
also a good criterion to test biological variability. Table 6.7 lists the top 10 signature JEPs
in diseased class in Michigan and Harvard datasets. The details about the sets of HDGGs
in these two datasets will be described in Chapter 7.
Note: In order to show more information, we leave ‘+’ and ‘-’ sign in the table, so the
patterns in the table are actually JEPs. When the signs are removed, each JEP will
become one HDGG. There are only 9 JEPs in original/refined Harvard dataset.
Table 6.7: HDGGs (JEPs) in Harvard and Michigan lung cancer datasets
Original datasets
Michigan
Harvard
{2910- }
{2910- }
{845- }
{3550- 4351- }
{1344- }
{3550- 3207- }
{1814- }
{2607- 3550- }
{2040- }
{2607- 2302- }
{3895- }
{2607- 1210+ }
{3136+ 483- }
{3550- 4351- }
{3136+ 483- }
{4351- 2302- }
{3136+ 5126- }
{4351- 1210+ }
{3136+ 65- }
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Refined datasets
Michigan
Harvard
{711-}
{640-}
{845-}
{845-}
{1344-}
{1344-}
{1814-}
{2607-}
{2040-}
{2287-}
{2275-}
{2688-}
{2287-}
{2910-}
{2956-}
{2607-}
{2910-}
{4351-}
{3136+}

Comparing the HDGGs mined from two lung cancer datasets, we find that only one
HDGG is shared by two original datasets (first & second columns) whereas five HDGGs
are shared by two C-loocv refined datasets (third & fourth columns).
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Chapter 7: DISCOVERY OF INVARIANT PATTERNS
7.1. MOTIVATION AND OUR APPROACH
During our microarray dataset study, we observed that the current microarray datasets we
focused on have very high variability. The existence of variability affects the quality and
transferability of mined patterns. In our study, among the mined HDGGs from one
dataset, it is difficult to tell which HDGGs are intrinsic patterns and which ones are
artifacts caused by variability. Most importantly, some intrinsic patterns may have been
covered up by the variability and can not be mined from such highly variable datasets.
Even though biological variability has been minimized by our C-loocv algorithm, other
factors also exist in microarray datasets that influence the mined patterns.
In order to better understand the mechanism underlying diseases, we will mine “invariant
patterns” from different datasets concerning a common disease. We define invariant
pattern (IVP) as following: if a pattern is a signature HDGG in one dataset and it has very
high support in all other datasets (even though it might not be a jumping emerging
pattern), we call this pattern an invariant pattern. In contrast, other HDGGs are defined
as variant patterns (VP).
In this chapter, (1) we mine both invariant patterns and variant patterns from multiple
microarray datasets concerning a common disease; (2) we prove that invariant patterns
are more related with the disease of interest than variant patterns; (3) we demonstrate
again that C-loocv is an effective algorithm for minimizing variability in datasets, and for
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helping us to mine more invariant patterns.
We hope that invariant patterns can help shed light on the mechanism of the given
disease underlying the given datasets based on the following rationale. If one pattern is
involved in the disease-specific gene interaction networks and pathways, this pattern is
very likely to be a HDGG, or to have very high "verification" frequency in any
microarray datasets concerning this disease. On the other hand, if a pattern has very high
frequency in one dataset, but has very low frequency in other datasets concerning the
same disease, it is more reasonable to deduce that this pattern might be an artifact caused
by noise or technical differences.

7.2. MATERIALS AND METHODS
We use the same lung cancer microarray datasets (namely Michigan and Harvard) as
used in Chapter 6. The details about them were described in Chapter 6. After treating the
datasets by C-loocv algorithm, we obtain two more datasets: Refined Michigan (RM) and
Refined Harvard (RH). For our convenience, the two datasets not treated with C-loocv
are called Original Michigan (OM) and Original Harvard (OH) respectively. Thus, totally
four datasets are studied in this chapter (OM, RM, OH and RH).
The method we use to mine invariant patterns from any two given microarray datasets is
the following: a) in each given microarray dataset, every gene’s expression value is
discretized as 0 or 1 using the entropy based method; b) the iterative gene club formation
algorithm and border differential algorithm are applied to mine HDGGs from each of the
dataset; c) the HDGGs mined from the diseased class in each dataset are collected; d) the
frequency of each HDGG is determined in both datasets; e) the invariant patterns are
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determined based on the HDGGs’ frequency in each dataset.
In this chapter, the above method will be applied to mine HDGGs and IVPs from dataset
pairs: one dataset from Michigan (original or refined) and the other one from Harvard
(original or refined). Specifically, we will mine HDGGs and IVPs from four pairs of
datasets (OM vs OH; RM vs OH; OM vs RH; RM vs RH) respectively. The data mining
results from dataset pairs (OM vs OH and RM vs RH) are of our great interest and will be
studied thoroughly. The results from dataset pairs RM vs OH and OM vs RH will be used
as reference.
After finding the invariant patterns and variant patterns, the known biological functions
of the discriminating genes within those patterns are investigated and evaluated. The
number and percentage of invariant patterns within mined HDGGs from different dataset
pairs are also compared and discussed.

7.3. RESULTS ON INVARIANT HDGG PATTERNS
Table 7.1 lists the HDGGs mined from OM and OH datasets. The columns from left to
right are: HDGG’s index, emerging patterns which include the involved discriminating
genes in the HDGG, frequency of the HDGG in the OM dataset, frequency of the HDGG
in the OH, and whether the HDGG is considered as an invariant pattern, respectively. We
use the frequency of 95% as threshold to determine whether a HDGG is an IVP, i.e. if
one HDGG’s frequency in both datasets is higher than 95%, we consider it as an IVP.
Otherwise, it is a VP.
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Table 7.1: IVPs and VPs from OM and OH datasets
Index
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Emerging patterns
{845 -}
{1344 -}
{1814 -}
{2040 -}
{2910 -}
{3895 -}
{3136 +, 483 -}
{3136 +, 4126 -}
{3136 +, 65 -}
{3136 +, 115 -}
{3136 +, 725 -}
{3136 +, 4228 +}
{3136 +, 3829 +}
{3136 +, 3925 +}
{3136 +, 1214 +}
{3136 +, 1722 +}
{3136 +, 2126 +}
{3136 +, 4757 +}
{483 -, 4228 +, 5126 -}
{483 -, 4228 +, 115 -}
{640 -}
{2688 -}
{2607 -, 3550 -}
{2607 -, 2302 -}
{2607 -, 1210 +}
{4351 - , 3550 -}
{4351 - , 2302 -}
{4351 - , 1210 +}
{2607 -, 2302 -}
{2607 -, 1210 +}
{2302 -, 4351 –}

Frequency in
OM (%)
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
97.7%
98.8%
97.7%
74.4%
8.1%
90.7%
67.4%
8.1%
74.4%
8.1%
67.4%

Frequency in
OH (%)
98.4%
97.8%
96.8%
88.7%
99.5%
97.3%
13.4%
5.4%
9.7%
1.1%
13.4%
13.4%
15.1%
12.4%
8.1%
8.1%
14.5%
12.9%
27.4%
12.4%
98.4%
98.4%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%

IVP
Y
Y
Y
Y
Y

Y
Y
Y

Among the 31 HDGGs mined from the two original datasets, 8 of them are IVPs because
their frequencies are higher than 95% in both datasets, and the other 23 HDGGs are VPs
which exhibit high frequency in only one dataset.
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Table 7.2 lists the IVPs and VPs mined from RM and RH datasets. A total of 26 HDGGs
are mined from these two datasets and 14 of them are IVPs.
Table 7.2: IVPs and VPs from RM and RH datasets
Index

Emerging patterns

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

{640 -}
{845 -}
{1344 -}
{1814 -}
{2040 -}
{2275 -}
{2287 -}
{2607 -}
{2910 -}
{3136 +}
{3581 -}
{3895 -}
{4020 -}
{2688 -}
{2956 -}
{4351 -}
{3284 -, 4657 -}
{3284 -, 796 +}
{3284 -, 2941 +}
{3284 -, 1600 +}
{3284 -, 3038 +}
{3284 -, 961 +}
{3284 -, 1035 +}
{3284 -, 1100 +}
{3284 -, 1797 +}
{3284 -, 3012 +}

Frequency
in RM (%)
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
98.8%
97.6%
100.0%
91.9%
90.7%
69.9%
20.5%
45.8%
30.1%
66.3%
13.3%
21.7%
69.9%

Frequency
in RH (%)
100.0%
100.0%
100.0%
99.4%
99.4%
40.3%
100.0%
100.0%
100.0%
2.3%
98.9%
98.9%
99.4%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

IVP
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

From these two Tables, we notice that biological variability has big impact on the mined
HDGGs. Some HDGGs have very high frequency in one dataset, but have quite low
frequency in the other dataset. For example, in Table 7.1, patterns {3136+, 115-}, {3136+,
65- } have 100% frequencies in OM dataset; but their frequencies are less than 10% in
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OH dataset. Patterns {4351- , 1210+}, {2607-, 1210+} have nearly 100% frequencies in
OH dataset, but have lower than 10% frequencies in OM. These results demonstrate that
biological variability greatly affects data mining result and reduce the quality of mined
HDGGs. Therefore, further study is needed to sort out real valuable HDGGs, which are
IVPs as our concern, for the understanding of diseases.
In the following sections, first we prove that IVPs are more related with cancer diseases
than VPs; then we demonstrate again that the C-loocv algorithm can effectively improve
the invariance of datasets.

7.3.1. Biological function comparison of the discriminating genes
within IVPs versus VPs
As shown in Table 7.2, 14 IVPs and 12 VPs are identified from two refined lung cancer
datasets (RM vs RH). In order to evaluate the quality of these patterns, one good and
direct way is to investigate the biological functions of each discriminating gene (DG) in
these patterns since the set of DGs (total 14 DGs) in IVPs are completely different from
that in VPs (total 13 DGs). Each discriminating gene’s function will be described in
Section 7.4.2.
Note: If there were overlapping of DGs in IVPs with those in VPs, we should have
further investigated the relationship between these DGs’ involved in one given HDGG.
According to the gene’s functions by biological studies, we find that among the 14 DGs
within IVPs, 7 DGs have been shown to be related with tumors. The ratio is 7/14 =
50.0%. In contrast, among the 13 DGs within VPs, only 3 genes have been proven to be
related with tumors, and the ratio is 3/13 = 23.1%.
In our cancer study, theoretically, if no variability exists in microarray datasets, all DGs
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in both IVPs and VPs should be related with tumors. Therefore, the above results indicate
that, using datasets with high variability, IVPs are more robust than VPs to understand
diseases. They may provide useful clues for finding some unknown gene’s functions and
for discovering the potential gene interactions in tumor occurrence.
We also investigated the functions of the discriminating genes listed in Table 7.1, which
were mined from the original datasets (OM vs OH). We randomly chose several
discriminating genes for function analysis and got similar results.

7.3.2. C-loocv effectively improves the quality of mined HDGGs
We compare the IVPs and VPs mined from different dataset pair combinations. These
HDGGs are listed in Table 7.1, 7.2, 7.4 and 7.5.
(1) The numbers of IVPs mined from the refined dataset pairs are larger than that from
the original ones. Meanwhile, the percentage of IVPs in HDGGs also increases (Table
7.3). Table 7.3 lists the number and the percentage of IVPs in HDGGs mined from 4
different dataset pairs.
Table 7.3: The number and percentage of IVPs mined from four dataset pairs
Index
1
2
3
4

Datasets
OM vs OH
OM vs RH
RM vs OH
RM vs RH

No. of IVPs
8
11
11
14

No. of HDGGs
31
36
22
26

% of IVPs
25.8%
30.6%
50.0%
53.8%

(2) Comparing the set of IVPs from different dataset pair, we notice that one IVP {2607,
3550} is mined from the original datasets; in contrast, a different IVP {2607} is mined
from the refined datasets, which is the subset of the former pattern. This means that one
discriminating gene 2607 may be enough to determine the disease. The occurrence of
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gene 3550 in pattern {2607, 3550} may be an artifact.
(3) Some IVPs fail to be mined from the original datasets, but they can be mined from the
refined datasets. By comparing the sets of IVPs mined from different dataset pairs in
Table 7.3, we find the relationship among the IVP sets: A ⊂ B ⊂ D, and A ⊂ C ⊂ D
(Figure 7.1). Here, A is the set of IVPs mined from dataset pair OM vs OH; B is IVP set
from OM vs RH; C is the IVP set from RM vs OH, and D is the IVP set from RM vs RH
dataset pair. Note: We consider the IVP {2607, 3550} and IVP {2607} as the same
pattern.

Figure 7.1: Relationship of the sets of IVPs from different dataset pairs
Several IVPs such as {2040}, {2956}, {4351}, which failed to be mined from the
original datasets, have very high frequency in both refined datasets. The discriminating
genes in these IVPs are proven to be related to tumors.
From the above results, we conclude that: (A) C-loocv effectively minimizes the
variability of microarray datasets; (B) C-loocv improves the overall quality of the
HDGGs with respect to IVPs mined from the refined datasets.

7.3.3. Discussion
In order to better understand diseases, we identified invariant patterns from multiple
datasets concerning a common disease. In this chapter, we obtained both invariant
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patterns and variant patterns from the datasets concerning lung cancer. Compared with
variant patterns, there is a higher proportion of discriminating genes in invariant patterns
which are known to be related to tumors. This suggests that invariant patterns are more
valuable for revealing the mechanism of specific diseases.
Our C-loocv algorithm, which was developed to minimize the biological variability of
datasets, can effectively help us to mine high-quality IVPs from microarray datasets.
Indeed, the quality of HDGGs mined from the C-loocv refined datasets is higher than that
from the original datasets.
95% of frequency was used as threshold to determine invariant patterns in this study. We
also tried 90% and 85% of frequency as thresholds and got similar results: (A) the
invariant patterns were more related with tumors than variant patterns; (B) the number
and the proportion of invariant patterns in mined HDGGs were higher from the refined
datasets than that from original datasets.
With the development of modern molecular biology, more and more genes have been
identified and sequenced. However, the specific functions of many genes are still
unknown or still under investigation. Functional genomics is a relatively new field of
molecular biology that attempts to use numerous known gene-sequence data to determine
unknown gene functions and interactions. It usually takes a long time to understand one
specific gene’s function. We hope that our data mining results can provide valuable clues
for gene function study.
According to our results, the genes in invariant patterns tend to be potentially important
for the occurrence of lung cancer. So far, more than 40% of the discriminating genes
within these IVPs have not been found to be functionally related with tumors. We
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recommend further study by biomedical scientists to determine the exact functions of
these genes.

7.4. APPENDIX
7.4.1. IVPs and VPs in OM vs RH and in RM vs OH datasets
Table 7.4 lists the IVPs and VPs mined from dataset OM vs RH. A total of 36 HDGGs
are mined from these two datasets and 11 of them are IVPs.
Table 7.4: IVPs and VPs from OM and RH dataset pair
Index
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Emerging patterns
{845 -}
{1344 -}
{1814 -}
{2040 -}
{2910 -}
{3895 -}
{3136 +, 483 -}
{3136 +, 5126 -}
{3136 +, 65 -}
{3136 +, 115 -}
{3136 +, 725 -}
{3136 +, 4228 +}
{3136 +, 3829 +}
{3136 +, 3935 +}
{3136 +, 1214 +}
{3136 +, 1722 +}
{3136 +, 2126 +}
{3136 +, 4757 +}
{483 -, 4228 +, 5126 -}
{483 -, 4228 +, 115 -}
{640 -}
{2287 -}
{2607 -}
{2688 -}
{2956 -}
{4351 -}
{3284 -, 4657 -}

Frequency in
OM (%)
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
97.7%
96.5%
98.8%
98.8%
96.5%
91.9%
91.9%
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Frequency in
RH (%)
100.0%
100.0%
99.4%
99.4%
100.0%
98.9%
2.3%
0.0%
1.1%
2.3%
2.3%
2.3%
2.3%
2.3%
0.0%
1.1%
2.3%
2.3%
9.7%
73.9%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

IVP
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y

28
29
30
31
32
33
34
35
36

{3284 -, 796 +}
{3284 -, 2941 +}
{3284 -, 1600+}
{3284 -, 3038 +}
{3284 -, 961 +}
{3284 -, 1035 +}
{3284 -, 1100 +}
{3284 -, 1797 +}
{3284 -, 3012 +}

90.7%
70.9%
20.9%
48.8%
66.3%
23.3%
34.9%
22.1%
72.1%

100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

Table 7.5 lists the IVPs and VPs mined from OH vs RM datasets. A total of 22 HDGGs
are mined from these two datasets and 11 of them are IVPs.
Table 7.5: IVPs and VPs from RM and OH datasets
Index

Emerging patterns

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

{845 -}
{1344 -}
{1814 -}
{2040 -}
{2275 -}
{2287 -}
{3136 +}
{3581 -}
{3895 - }
{4020 -}
{2910 -}
{640 -}
{2688 -}
{2607 -, 3550 -}
{2607 -, 2302 -}
{2607 -, 1210 +}
{4351 -, 3550 -}
{4351 -, 2302 -}
{4351 -, 1210 +}
{2607 -, 2302 -}
{2607 -, 1210 +}
{2302 -, 4351 -}

Frequency in
RM (%)
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
98.8%
100.0%
68.7%
8.4%
100.0%
68.7%
8.4%
68.7%
8.4%
68.7%
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Frequency in
OH (%)
98.4%
97.8%
96.8%
88.7%
58.1%
96.2%
15.6%
80.1%
97.3%
95.2%
99.5%
98.4%
98.4%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%
99.5%

IVP
Y
Y
Y

Y

Y
Y
Y
Y
Y
Y

Y

7.4.2. Biological functions of the related genes
Table 7.6 lists the genes that are involved in the IVPs and HDGGs mined from both the
original datasets and the refined datasets. In this section, we introduce the genes listed in
Table 7.2 and the known functions of these genes. Meanwhile, we also randomly choose
several genes from Table7.6 and discuss their functions.
Table 7.6: Description of DGs involved in HDGGs in Tables 7.1 and 7.2
Index
number
1

Gene
number
65

Uni gene
name
GTF2B

2
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RPS6KA1

3

483

POLR2C

4

640

PTPRH

5

725

KDR

6

796

CTNNA2

7

845

FRAP1

8
9
10

961
1035
1100

RPL18
ANXA3
DRP2

11

1210

VAMP2

12

1214

ZNF345

13

1344

PPP3CC

14
15
16
17

1600
1722
1797
1814

FXN
MAGEA2
DDT
PTPRU

18

2040

SLC2A5

19
20

2126
2275

MAGEA5
3.8-1

21

2287

SGCD

22
23

2302
2607

OPRK1
ZNF268

Description
general transcription factor IIB
ribosomal protein S6 kinase, 90kDa, polypeptide
1
polymerase (RNA) II (DNA directed)
polypeptide C, 33kDa
protein tyrosine phosphatase, receptor type, H
kinase insert domain receptor (a type III receptor
tyrosine kinase)
catenin (cadherin-associated protein), alpha 2
FK506 binding protein 12-rapamycin associated
protein 1
ribosomal protein L18
annexin A3
dystrophin related protein 2
vesicle-associated membrane protein 2
(synaptobrevin 2)
zinc finger protein 345
protein phosphatase 3 (formerly 2B), catalytic
subunit, gamma isoform (calcineurin A gamma)
Frataxin
melanoma antigen family A, 2
D-dopachrome tautomerase
protein tyrosine phosphatase, receptor type, U
solute carrier family 2 (facilitated
glucose/fructose transporter), member 5
melanoma antigen family A, 5
MHC class I mRNA fragment 3.8-1
sarcoglycan, delta (35kDa dystrophin-associated
glycoprotein)
opioid receptor, kappa 1
zinc finger protein 268
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24
25
26
27
28
29
30

2688
2910
2941
2956
3012
3038
3136

NCOA1
RNF113A
MDH1
HSD17B4
CAMP
NEUROD1
ERP29

31

3284

CYP11A1

32
33
34
35
36

3550
3581
3829
3895
3925

BLMH
GLB1
PENK
FASN
TARS

37

4020

ATP6V0D1

38

4126

AGC1

39
40
41

4228
4351
4657

CD3G
PRM1
CCT5

42

4757

KCNB1

43

5126

HTATIP

nuclear receptor coactivator 1
ring finger protein 113A
malate dehydrogenase 1, NAD (soluble)
hydroxysteroid (17-beta) dehydrogenase 4
cathelicidin antimicrobial peptide
neurogenic differentiation 1
endoplasmic reticulum protein 29
cytochrome P450, family 11, subfamily A,
polypeptide 1
bleomycin hydrolase
galactosidase, beta 1
Proenkephalin
fatty acid synthase
threonyl-tRNA synthetase
ATPase, H+ transporting, lysosomal 38kDa, V0
subunit d1
aggrecan 1 (chondroitin sulfate proteoglycan 1,
large aggregating proteoglycan, antigen
identified by monoclonal antibody A0122)
CD3g molecule, gamma (CD3-TCR complex)
protamine 1
chaperonin containing TCP1, subunit 5 (epsilon)
potassium voltage-gated channel, Shab-related
subfamily, member 1
HIV-1 Tat interacting protein, 60kDa

Gene 65 (general transcription factor IIB): general transcription factor IIB is a ubiquitous
factor required for transcription initiation by RNA polymerase II. It was suggested that
TFIIB serves as a bridge between the "TATA"-binding factor (TFIID) and RNA
polymerase II during pre-initiation complex assembly. Recently, it was also found that
GTFIIB can be a target of acidic activators.
Gene 483 (polymerase (RNA) II (DNA directed) polypeptide C, 33kDa): This gene
encodes the third largest subunit of RNA polymerase II, the polymerase responsible for
synthesizing messenger RNA in eukaryotes. The product of this gene contains a cysteine
rich region and exists as a heterodimer with another polymerase subunit, POLR2J. These
two subunits form a core subassembly unit of the polymerase. The expression of this
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gene is regulated during muscle differentiation (Corbi et al 2005).
Gene 640 (PTPRH) and gene 1814 (PTPRU): The proteins encoded by these two genes
are a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be
signaling molecules that regulate a variety of cellular processes including cell growth,
differentiation, mitotic cycle, and oncogenic transformation. The genes were shown to be
expressed primarily in brain and liver, and at a lower level in heart and stomach. It was
also found that these two genes expressed in several cancer cell lines, but not in the
corresponding normal tissues (Trapasso et al 2004).
Gene 796 (catenin (cadherin-associated protein), alpha 2): The protein encodes by this
gene is a subunit of alpha N-catenin, a linker between cadherin adhesion receptors and
the actin cytoskeleton. It is essential for stabilizing dendritic spines in rodent
hippocampal neurons in culture. It has been proven that alpha N-catenin is a key
regulator for the stability of synaptic contacts (Abe et al 2004).
Gene 845 (FK506 binding protein 12-rapamycin associated protein 1 or Frap1): The
protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related
kinases. The known function for this protein is kinase activity and binding. It has been
reported that Frap is a candidate gene for the plasmacytoma resistance locus Pctr2 and
can act as a tumor suppressor gene (Bliskovsky et al 2003).
Gene 961 (ribosomal protein L18): This gene encodes the large subunit of ribosomal
protein. This is one of the proteins that binds and probably mediates the attachment of the
5S RNA into the large ribosomal subunit, where it forms part of the central protuberance.
Gene 1035 (annexin A3): ANXA3 is present in healthy epithelial cells, and is relatively
less abundant in individual tumor cells of increasing Gleason pattern (GP), despite
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exhibiting higher overall tissue abundance in tumors. ANXA3 staining was
predominantly cytoplasmic. Strongly staining single cells, possibly phagocytes, were
interspersed in highly dedifferentiated GP5 tumor areas among tumor cells without
measurable ANXA3. (Wozny et al 2007).
Gene 1100 (dystrophin related protein 2): DRP protein is the members of the dystrophin
family, which performs a critical role in the maintenance of membrane-associated
complexes at points of intercellular contact in vertebrate cells. Dystrophin related protein
2 is predicted to resemble certain short C-terminal isoforms of dystrophin and dystrophinrelated protein 1 (DRP1 or utrophin). DRP2 is expressed principally in the brain and
spinal cord.
Gene 1210(vesicle-associated membrane protein 2 (synaptobrevin 2)): Vesicle-associated
membrane protein (VAMP) (or synaptobrevin), a type II membrane protein of small
synaptic vesicles, is essential for neuroexocytosis because its proteolysis by tetanus and
botulinum neurotoxins types B, D, F and G blocks neurotransmitter release. It implies the
existence of a synaptophysin-VAMP-2 complex is helpful for the processes of vesicle
docking and fusion with the presynaptic membrane (Washbourne et al 1995).
Gene 1344 (protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform
(calcineurin A gamma)): The putative function of this gene includes: Calcium-dependent,
calmodulin-stimulated protein phosphatase. This subunit may have a role in the
calmodulin activation of calcineurin.
Gene 1600 (frataxin): Frataxin is a small protein, localized to the mitochondrion. The
function of frataxin is not entirely clear, but it seems to be involved in assembly of
irosulfur clusters. Deficiency of frataxin is the cause of Friedrich’s ataxia, a hereditary
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trinucleotide repeat disorder.
Gene 1797 (D-dopachrome tautomerase): This gene’s expression is tightly related with
Macrophage migration inhibitory factor (MIF) activity. When UVB light was used to
induce an experimental inflammation in normal human skin, the D-dopachrome
tautomerase’s expression increases significantly accomplishing with skin’s inflammation
(Sonesson et al 2003).
Gene 2040 (solute carrier family 2 (facilitated glucose/fructose transporter), member 5):
Another name of this gene is GLUT5, which is expressed on the brush border membrane
of human small intestinal enterocytes (Davidson et al 1992). GLUT5 is a fructose
transporter and may be largely responsible for the uptake of fructose from the lumen of
the small intestine (Burant et al 1992). Godoy and colleagues (Godoy et al 2006) used
situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 overexpression in breast cancer. The extensive expression of GLUT2 and 5 (glucose/fructose
and fructose transporters, respectively) in malignant human tissues indicates that fructose
may be a good energy substrate in tumor cells.
Gene 2275 (MHC class I mRNA fragment 3.8-1): specific function is under investigation.
Gene 2287 (sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)): The protein
encoded by this gene is one of the four known components of the sarcoglycan complex,
which is a subcomplex of the dystrophin-glycoprotein complex (DGC). DGC forms a
link between the F-actin cytoskeleton and the extracellular matrix. This protein is
expressed most abundantly in skeletal and cardiac muscle. The mutations in this gene
have been associated with autosomal recessive limb-girdle muscular dystrophy and
dilated cardiomyopathy. Alternatively spliced transcript variants encoding distinct
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isoforms have been observed.
Gene 2607 (zinc finger protein 268): ZNF268 plays a role in the development of human
fetal liver and the differentiation of blood cells. There are many splicing isoforms of ZNF
268 genes. ZNF268c mRNA was detected only in tumor cells. ZNF268a, ZNF268b1 and
ZNF268b2, were also detected in tumor cell lines (Shao et al 2006).
Gene 2688 (nuclear receptor coactivator 1): The nuclear receptor coactivator 1(NCOA1)
is a transcriptional co-reluatory protein which is recruited to DNA promotion sites by
ligand activated nuclear receptors. NCOA1 accumulates histone which makes
downstream DNA more accessible to transcription. NCOA1 is also frequently called
steroid receptor coactivator-1(SRC-1). It has been reported that enhanced androgen
receptor activity through elevated expression of SRC-1 in the development of more
aggressive disease in men with prostate cancer (Agoulnik et al 2005).
Gene 2910 (RNF 113A): RNF 113A is also called RNF113 or ZNF183 which encodes a
ring finger protein 113A. It is a novel gene whose function cannot directly be inferred
from its sequence analysis. RNF113A is a ubiquitously expressed protein that contains a
RING type zinc finger and a C3H1 type zinc finger.
Gene 2941 (malate dehydrogenase 1, NAD (soluble)): Malate dehydrogenase catalyzes
the reversible oxidation of malate to oxaloacetate, utilizing the NAD/NADH cofactor
system in the citric acid cycle. The protein encoded by this gene is localized to the
cytoplasm and may play pivotal roles in the malate-aspartate shuttle that operates in the
metabolic coordination between cytosol and mitochondria.
Gene 2956 (hydroxysteroid (17-beta) dehydrogenase 4): The peroxisomal 17βhydroxysteroid dehydrogenase type 4 (17β-HSD 4, gene name HSD17B4) catalyzes the
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oxidation of estradiol with high preference over the reduction of estrone. The expression
of 17β-HSD 4 has been detected in several human cancer cell lines (Launoit et al 1999).
Gene 3012 (cathelicidin antimicrobial peptide): The cathelicidin antimicrobial peptide
(CAMP) is an important innate defense peptide. It showed the expression of CAMP in
nasal mucosa supporting its role in innate defenses against inhaled pathogens (Ooi et al
2007).
Gene 3038 (neurogenic differentiation 1): This gene encodes a member of the NeuroD
family of basic helix-loop-helix (bHLH) transcription factors. The protein forms
heterodimers with other bHLH proteins and activates transcription of genes that contain a
specific DNA sequence known as the E-box. It regulates expression of the insulin gene,
and mutations in this gene result in type II diabetes mellitus.
Gene 3136(ERp29): ERp29 is a recently discovered ER resident that has been implicated
in secretory protein synthesis and appears to be of similar prevalence to the established
major reticuloplasmins (Hubbard et al. 2000). The novel protein sequence of ERp29
exhibits characteristic features of a reticuloplasmin (signal peptide, ER retention motif),
and localization to the ER lumen was comprehensively supported at the biochemical level
(Demmer et al. 1997). Hubbard found that cancer cells have more ERp29 than normal
cells, and suggested that if it does help make key cellular components, perhaps it could be
targeted at preventing cancer growth (Shnyder S., Hubbard M., 2002).
Gene 3284 (cytochrome P450, family 11, subfamily A, polypeptide 1): This gene
encodes a member of the cytochrome P450 superfamily of enzymes. The encoded
enzyme catalyzes many reactions involved in drug metabolism and synthesis of
cholesterol, steroids and other lipids which includes the biosynthesis of sex-steroid
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hormones. Recently, the relationship between common variation in CYP11A and breast
cancer risk among African-Americans, Latinas, Japanese-Americans, native Hawaiians
have been reported (Setiawan et al 2006).
Gene 3550 (bleomycin hydrolase): The normal physiological role of BLM hydrolase is
unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by
hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting
normal and malignant cells from BLM toxicity.
Gene 3581 (galactosidase, beta 1): galactosidase, beta 1 encodes a protein called betagalactosidase. A deficiency of (GLB1) causes G(M1)-gangliosidosis which is a
lysosomal storage disorder (Caciotti et al 2005).The GLB1 gene gives rise to the GLB1
lysosomal enzyme and to the elastin binding protein (EBP), involved in elastic fiber
deposition.
Gene 3895 (Fatty acid synthase): Fatty acid synthase (FAS) is a multienzyme protein
required for the conversion of acetyl coenzyme A and malonyl coenzyme A to palpitate.
High levels of FAS expression have been found in many human cancers, including breast,
prostate and colon (Notarnicola et al 2006).
Gene 4020 (ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1): This gene
encodes a protein or proteins that contain an ATPase, V0/V1 complex. It is implied that
this gene is in the proton-transporting two sector ATPase complex, which is involved in
ATP synthesis coupled proton transport. The function of this enzyme is a hydrogen ion
transporting ATPase activity, rotational mechanism and a hydrogen ion transporting ATP
synthase activity, rotational mechanism protein.
Gene 4351(protamine 1): Gene 4351 encodes a protein called Protamines. Protamines is
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a kind of sperm nuclear protein, which is directly related with male infertility (Iguchi et al,
2006).
Gene 4657 (chaperonin containing TCP1, subunit 5 (epsilon)): This gene encodes a
molecular chaperone that is member of the chaperonin containing TCP1 complex (CCT),
also known as the TCP1 ring complex (TRiC). The complex folds various proteins,
including actin and tubulin. Alternate transcriptional splice variants of this gene have
been observed but have not been thoroughly characterized.
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Chapter 8: CONCLUSION AND DISCUSSION

Microarrays enable high-throughput parallel gene expression analysis, and their use has
grown exponentially during the past decade. We are now in a position where suitable data
mining results using the public microarray datasets can be used to identify hypothesis
about various biological mechanisms. Comparative microarray data mining could better
distinguish phenotypes, propose new hypothesis, identify differentially expressed genes,
and discover fundamental patterns of gene expression and regulation.
In this chapter, we will give a brief summary of this dissertation about comparative study
of microarray data mining, and highlight some major contributions. Meanwhile, some
future research directions are also described based on the results of this dissertation.

8.1. SUMMARY
In this dissertation, we used comparative data mining methods to study certain public
microarray datasets. Our goal is to mine intrinsic patterns from cancer related public
microarray datasets and to provide valuable clues for biologists to further study cancer
diseases. In order to reach this goal, we provided novel methods for testing the
concordance of microarray datasets generated from multi-platforms and multilaboratories, investigating the effect of biological variability on our data mining results,
and finally, mining invariant patterns from multi-microarray datasets. We believe that
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such patterns could provide valuable information for future cancer study.
Below is a brief summary of this dissertation in a Chapter-by-Chapter manner.
In Chapter 1, we gave the motivations and set the research goal for our study. We also
highlighted the outline of this dissertation and briefly introduced the results obtained in
this dissertation.
In Chapter 2, we presented some preliminaries on the techniques and terminologies that
were used throughout this dissertation. This chapter introduced the high dimensional
microarrays, the procedure of microarray data generation, the characteristics of
microarray datasets, emerging patterns, border differential algorithms, entropy based
discretized method, information gain and so on.
In Chapter 3, we surveyed the existing works related to the topics studied in this
dissertation. We discussed the researches reported by previous papers, and most
importantly, we identified the gaps between previous studies and our current research
goal. What we did in our research was to fill those gaps. We focused on the following
topics: comparative microarray gene expression data mining, feature selection,
microarray data concordance detection, instance selection, and classification etc.
In Chapter 4, we combined a new feature selection approach with a previous data mining
algorithm to discover emerging patterns, which are named highly differentiative gene
groups (HDGGs). The HDGGs mined from one dataset are considered as discriminative
characteristic patterns and HDGGs are important features for each specific dataset.
Since there are more than thousands of dimensions in microarray data, it is a big
challenge to mine HDGGs. In Chapter 4, we introduced novel methods that did a better
job to overcome the high dimensionality challenge. To be specific, first, we provided new
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ideas to create a relatively small gene group called gene club. Within one gene club, all
genes are potentially interactive with each other. Next, we applied border differential
algorithm to mine HDGGs from the original data projected on each given gene club.
Some genes in mined HDGGs have been confirmed to be related with cancer diseases.
Finally, HDGGs have also been used to build classifiers, which are named HDGG-based
classifiers.
In Chapter 5, we provided novel measures and techniques to test the concordance of
microarray gene expression data. Microarray data were collected using different
microarray platforms (provided by different companies) under different conditions in
different laboratories. It is necessary to test if these microarray data are comparable,
reliable and consistent before they can be applied for clinical, pharmaceutical research
and other purposes.
In previous studies, the cross platform and cross lab concordance of microarray data have
been tested with many methods, such as biological experiments, statistical methods and
so on. But the platform/lab concordance has not been examined with comparative method
yet. It has been realized that different testing methods may lead to different results.
Therefore, in Chapter 5, we developed several novel comparative methods to examine the
concordance of datasets from cross platforms/labs.
In Chapter 6, we defined the degree of variability in microarray datasets, developed
measurements for testing the variability, and investigated the effect of variability on our
data mining results. To be specific, we studied the effect of two types of variability,
measurement variability and biological variation, in microarray datasets.
We also provided novel method (C-loocv) to minimize the biological variability. After
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biological variability was minimized, the data mining results from refined datasets were
evaluated, and showed a good improvement of the reliability. More importantly, the
HDGG-based classifiers trained from refined datasets became more robust, and predicted
test samples with much higher accuracy.
In Chapter 7, we discovered certain invariant patterns from multiple microarray datasets
concerning a common disease. We studied two microarray datasets derived from the
samples of patients with common disease. These datasets were generated from a common
platform but different laboratories. We mined HDGGs from each dataset and discovered
the shared gene interactions (which are called invariant patterns) by comparing these
HDGGs’ generality and specificity among different datasets. Since variability affects the
data mining results, the invariant patterns should be more reliable to provide useful
information for understanding the potential gene pathways for diseases.
In the above 7 chapters we presented our approaches for comparative microarray data
mining. Experimental evaluations have been conducted for those proposed approaches,
and the results showed that our approaches are very promising and effective. However,
limitations were also observed in some of the approaches, which have been suggested as
potential future works.

8.2. CONTRIBUTIONS
Overall, we made the following contributions in this dissertation:
(1) We conducted extensive study to mine HDGGs from high dimensional microarray
datasets. Our methods are better than previous studies in many ways including: (A) we
improved the strength of discovered patterns compare with previous studies; (B) we
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discovered strongest HDGGs (100% frequency); (C) our HDGGs were proven to be
biological meaningful; (D) the discovered HDGGs were used to build the so-called
HDGG-based classifiers, which showed higher predicting accuracy on many public
microarray datasets compared with other classifiers.
(2) Using comparative methods, we quantitatively tested the concordance of microarray
datasets collected from same/different platforms and different laboratories. This was the
first attempt to use comparative methods for evaluating microarray dataset concordance.
We tested four popular, commercial platforms: Applied Biosystem (ABI), Affymetrix
(AFX), Agilent one color array (AG1) and GE Healthcare (GEH). Our results showed
that the datasets from any common platform but different laboratories were highly
concordant; the datasets from different platforms were also concordant with each other
except the datasets generated from the Agilent one color array platform.
(3) This dissertation was the first attempt to define the degree of variability, measure the
effect of variability on data mining results, and minimize variability in microarray
datasets. After variability was minimized by C-loocv algorithm, the data mining results
from datasets became more consistent. Furthermore, the robustness of our HDGG-based
classifiers built from C-loocv refined datasets was significantly improved.
(4) We provided novel method to mine high quality patterns from highly variable
microarray datasets. The so-called “invariant patterns” have been proven to be more
reliable for helping understand diseases, and they tend to be potentially important for the
occurrence of diseases.
We believe that those contributions not only are useful for DNA microarray dataset
studies, but also provide valuable information for pharmaceutical and clinical research.
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8.3. FUTURE WORKS
While the work in this dissertation has addressed many problems of current microarray
data mining, it could only do so with a limited depth. We believe that this dissertation has
laid the foundation for a wide variety of potential research and applications. There are
several relevant research topics that remain open:

A. Classification method improvement
In microarray data study, good classifiers are very important for accurately predicting the
samples (patients) and diagnosing the diseases. Many classification methods have been
developed. Currently, no classifier can predict the test samples with 100% accuracy in
any datasets. Therefore, newer classifiers with higher predicting ability still need to be
developed. HDGG-based classifiers building from HDGGs have been proven to be very
robust. Invariant patterns can be used to improve the reliability of HDGG based
classifiers. IVP-based classifiers building from IVPs are expecting to be more reliable.

B. Studying more microarray datasets which focus on any common
disease
In this dissertation, we provided generic methods to effectively identify valuable patterns,
aiming to shed light on the intrinsic mechanism underlying diseases of interest. For our
study, we used lung cancer related microarray datasets to mine invariant patterns. For
future research, our methods may be employed for microarray datasets concerning other
tumors or diseases. When IVPs are mined from multi-microarray datasets which study a
common disease, they will be of great help for understanding the mechanism of any
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given diseases.

C. Comparative study on multiple diseases
It is also desirable to study microarray datasets which study multiple diseases. By
comparing IVPs’ generality and specificity among the datasets which study different
diseases, the shared and unique gene interactions may be discovered and the shared and
unique gene networks may be established. The information for the potential gene
pathways for the set of diseases may also be provided.
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